Document:

Exhibit 10.15 - Lease Agreement with JWL Properties, LLC

                                LEASE AGREEMENT

SHOPPING CENTER:  PEACHTREE CENTRE

LOCATION:         NEW ALBANY, INDIANA

LANDLORD:         JWL PROPERTIES LLC

TENANT:           COMMUNITY BANK SHARES

--------------------------------------------------------------------------------
                                       96
<PAGE>

<TABLE>
<S>                                                                              <C>
Article I. GRANT AND TERM....................................................    12

         Section 1.01 - Premises:............................................    12

         Section 1.02 - Site Plan:...........................................    12

         Section 1.03 - Term:................................................    12

Article II. RENT.............................................................    12

         Section 2.01 - Minimum Rent:........................................    12

         Section 2.02 - Percentage Rent: - Intentionally Omitted.............    12

         Section 2.03 - Gross Sales Defined:.................................    12

         Section 2.04 - Tenant's Books and Records:..........................    12

         Section 2.05 - Payments by Tenant:..................................    12

         Section 2.06 - Security Deposit:....................................    12

         Section 2.07 - Late Charge:.........................................    12

         Section 2.08 - Returned Checks:.....................................    12

Article III. PREPARATION OF PREMISES.........................................    12

         Section 3.01 - Landlord's Work:.....................................    12

         Section 3.02 - Delivery Date:.......................................    12

         Section 3.03 - Tenant's Work:.......................................    12

         Section 3.04 - Alterations by Tenant:...............................    12

         Section 3.05 - Remodel:.............................................    12

Article IV. CONDUCT OF BUSINESS..............................................    12

         Section 4.01 - Use and Trade Name:..................................    12

         Section 4.02 - Operation of Business:...............................    12

         Section 4.03 - Utilities:...........................................    12

         Section 4.04 - Sprinkler Charge:....................................     7

         Section 4.05 - Sign:................................................    12

         Section 4.06 - Tenant's Warranties:.................................    12

         Section 4.07 - Legal Requirements:..................................    12

         Section 4.08 - Competition:.........................................     9

         Section 4.09 - Hazardous Materials:.................................    12

         Section 4.10 - Relocation:..........................................    12

Article V. COMMON AREA.......................................................    12

         Section 5.01 - Definition:..........................................    12

         Section 5.02 - Use:.................................................    12

         Section 5.03 - Common Area Expenses:................................    12

Article VI. REPAIRS AND MAINTENANCE..........................................    12

         Section 6.01 - Landlord's Obligations:..............................    12

         Section 6.02 - Tenant's Obligations:................................    12

Article VII. REAL ESTATE TAXES...............................................    12

         Section 7.01 - Liability:...........................................    12

         Section 7.02 - Method of Payment:...................................    12
</TABLE>

--------------------------------------------------------------------------------
                                       97
<PAGE>

<TABLE>
<S>                                                                              <C>
Article VIII. INSURANCE......................................................    12

         Section 8.01 - Landlord's Obligations:..............................    12

         Section 8.02 - Tenant's Contribution Towards Landlord's Insurance:..    12

         Section 8.03 - Tenant's Obligations:................................    12

         Section 8.04 - Covenants to Hold Harmless:..........................    12

         Section 8.05 - Liability of Landlord to Tenant:.....................    12

Article IX. DESTRUCTION OF PREMISES..........................................    12

         Section 9.01 - Continuance of Lease:................................    12

         Section 9.02 - Reconstruction; Rent Abatement:......................    12

Article X. CONDEMNATION......................................................    12

         Section 10.01 - Eminent Domain:.....................................    12

Article XI. ASSIGNING, SUBLETTING AND ENCUMBERING LEASE......................    12

         Section 11.01 - Assigning, Subletting and Encumbering Lease:........    12

Article XII. SUBORDINATION AND FINANCING.....................................    12

         Section 12.01 - Subordination:......................................    12

         Section 12.02 - Attornment:.........................................    12

         Section 12.03 - Financing:..........................................    12

         Section 12.04 - Estoppel:...........................................    12

Article XIII. DEFAULTS.......................................................    12

         Section 13.01 - Events of Default:..................................    12

         Section 13.02 - Landlord's Remedies:................................    12

         Section 13.03 - Additional Remedies and Waivers:....................    12

         Section 13.04 - Default by Landlord:................................    12

Article XIV. BANKRUPTCY OR INSOLVENCY........................................    12

         Section 14.01 - Tenant's Interest Not Transferable:.................    12

         Section 14.02 - Landlord's Option to Terminate:.....................    12

         Section 14.03 - Tenant's Obligation to Avoid Creditors' Proceedings:    12

         Section 14.04 - Application of Bankruptcy Proceeds:.................    12

         Section 14.05 - Bankruptcy:.........................................    12

Article XV. RIGHT OF ACCESS..................................................    12

         Section 15.01 - Right of Access:....................................    12

Article XVI. DELAYS..........................................................    12

         Section 16.01 - Delays:.............................................    12

Article XVII. END OF TERM....................................................    12
</TABLE>

--------------------------------------------------------------------------------
                                       98
<PAGE>

<TABLE>
<S>                                                                              <C>
         Section 17.01 - Return of Premises:.................................    12

         Section 17.02 - Holding Over:.......................................    12

Article XVIII. COVENANT OF QUIET ENJOYMENT...................................    12

         Section 18.01 - Covenant of Quiet Enjoyment:........................    12

Article XIX. MISCELLANEOUS...................................................    12

         Section 19.01 - Interpretation:.....................................    12

         Section 19.02 - Notice:.............................................    12

         Section 19.03 - Applicable Laws:....................................    12

         Section 19.04 - Successors:.........................................    12

         Section 19.05 - Limitation on Landlord's Personal Liability:........    12

         Section 19.06 - Brokers:............................................    12

         Section 19.07 - Landlord Assignment:................................    12

         Section 19.08 - Relationship of the Parties:........................    12

         Section 19.09 - Waiver of Right of Redemption:......................    12

         Section 19.10 - Waiver of Jury Trial:...............................    12

         Section 19.11 - Invalidity of Particular Provisions:................    12

         Section 19.12 - Strict Performance:.................................    12

         Section 19.13 - Tenants' Association:...............................    12

         Section 19.14 - Financial Disclosures:..............................    12

         Section 19.15 - Execution in Counterparts:..........................    12

         Section 19.16 - Execution of Lease by Landlord:.....................    12

         Section 19.17 - Security Agreement:.................................    12

         Section 19.18 - Effect of Captions:.................................    12

         Section 19.19 - Recording:..........................................    12

         Section 19.20 - Confidentiality:....................................    12

EXHIBIT A -  SITE PLAN.......................................................   A-1

EXHIBIT B -  LANDLORD'S WORK.................................................   B-1

EXHIBIT C - TENANT'S WORK....................................................   C-1

CONSTRUCTION ALLOWANCE RIDER.................................................     1

GUARANTY OF LEASE............................................................     2
</TABLE>

                                       99
<PAGE>

                                 LEASE AGREEMENT

      THIS LEASE AGREEMENT ("Lease") is made as of the _______day of June, 2003,
by and between JWL PROPERTIES LLC, a Kentucky Limited Liability Company
("Landlord"), with its principal office at 3211 Grant Line Road, Suite 7, New
Albany, Indiana, 47150, and COMMUNITY BANK SHARES OF INDIANA INC, an Indiana
corparation ("Tenant"), with its principal office at 101 W Spring St. New Albany
Indiana 47150.

                                 GRANT AND TERM

Premises:

      Landlord hereby leases to Tenant for the term and upon the covenants
hereinafter set forth, approximately 2,000 square feet of ground floor area plus
two drive through lanes with canopy ("Premises") in the shopping center,
designated as Peachtree Centre, or by such other name as Landlord may, from time
to time hereafter designate ("Shopping Center"). The Premises are cross-hatched
on the site plan of the Shopping Center, attached hereto and made a part hereof
as Exhibit "A". The exact square footage in the Premises shall be determined by
Landlord's architect. Such square footage shall be measured from the mid-line of
interior walls and the exterior part of exterior walls, and shall include the
totality of the area within such boundaries, including any mezzanines. The
certificate of Landlord's architect as to square footage shall be binding upon
both parties hereto. In the event the square footage, as determined by
Landlord's architect, differs from the square footage set forth above, the
Minimum Rent to be paid by Tenant as set forth in Article II shall be adjusted
after the exact square footage is determined by multiplying the square footage
by the amount(s) per square foot as set forth in Section 2.01 of this Lease, and
the respective Break Point(s) shall be adjusted accordingly.

Site Plan:

      Exhibit "A" sets forth the planned general layout of the Shopping Center.
Landlord does not warrant or represent that the Shopping Center will be or has
been constructed exactly as shown thereon or that it will be completed by a
specific date. Indeed, in the event that Landlord should elect not to construct
the Shopping Center for any reason whatsoever, Landlord may terminate this Lease
by written notice to Tenant provided on or before April 30, 2004. In any event,
Landlord may change or alter any of the stores, Common Areas (herein defined) or
any other aspect of the Shopping Center, or may sell or lease any portions of
the Shopping Center all without the consent of or notice to Tenant. This Lease
is subject to all applicable building restrictions, planning and zoning
ordinances, governmental rules and regulations, and all other encumbrances,
restrictions and easements affecting the Shopping Center and the terms and
provisions of certain declarations, reciprocal easement and operating agreements
now or hereafter affecting the Shopping Center.

Term:

      The term of this Lease shall be for a period of ten (10) Lease Years
commencing on (i) the expiration of a thirty (30) day period (the "Fixturing
Period") after the "Delivery Date" (herein defined) or, (ii) the date on which
Tenant shall open for business at all or any part of the Premises, whichever
occurs first ("Term Commencement Date"), and expiring midnight on the last day
of the month in which the tenth (10th) anniversary of the Term Commencement Date
occurs, unless sooner terminated in accordance with the provisions hereof
("Expiration Date"). The term "Lease Year" as used in this Lease shall be
defined to mean each successive twelve (12) month period commencing on the Term
Commencement Date. If the term commences on a day other than the first day of
the month, then the first Lease Year shall be extended for such a fractional
month. All subsequent Lease Years shall continue for twelve (12) calendar months
thereafter, except that the last Lease Year shall terminate on the date this
Lease is terminated. Within thirty (30) days after the Term Commencement Date,
Landlord and Tenant shall enter into a supplemental agreement prepared by
Landlord which affirms the Delivery Date, Term Commencement Date, and the
Expiration Date.

                                      RENT

Minimum Rent:

      Commencing on the Term Commencement Date and continuing during the entire
term of this Lease, Tenant shall pay annual "Minimum Rent" for the Premises
payable to Landlord, without demand, deduction, set-off or counterclaim, in
equal installments ("Monthly Minimum Rent") in advance, on or before the first
(1st) day of each month, as follows:

      LEASE YEARS            ANNUAL RENT      MONTHLY RENT
      -----------            -----------      ------------

      1-5                    $79,200.00          $6,600.00
      6-10                   $87,120.00          $7,260.00

--------------------------------------------------------------------------------
                                      100
<PAGE>

      The first installment of Minimum Rent shall be paid upon the Term
Commencement Date. If the Term Commencement Date occurs on other than the first
(1st) day of a month, Minimum Rent shall be prorated on a daily basis on the
basis of a thirty (30) day month.

Percentage Rent: - Intentionally Omitted.

Gross Sales Defined:-Intentionally Omitted

Tenant's Books and Records:-Intentionally Omitted

Payments by Tenant:

      Throughout the term of this Lease, Tenant shall pay to Landlord, without
demand, deductions, set-offs or counterclaims, the rent, which is hereby defined
as the sum of the Minimum Rent and all Additional Rent, when and as the same
shall be due and payable hereunder. Unless otherwise stated, all sums of money
or charges payable to Landlord from Tenant by this Lease, other than Minimum
Rent, are defined as "Additional Rent" and are due ten (10) days after the
rendering of an invoice therefore, without any deductions, set-offs or
counterclaims, and failure to pay such charges carries the same consequences as
Tenant's failure to pay Minimum Rent. All payments and charges required to be
made by Tenant to Landlord hereunder shall be payable in coin or currency of the
United States of America, at the address indicated herein. No payment to or
receipt by Landlord of a lesser amount than that then amount required to be paid
hereunder shall be deemed to be other than on account of the earliest amount of
such obligation then due hereunder. No endorsement or statement on any check or
other communication accompanying a check for payment of any amounts payable
hereunder shall be deemed an accord and satisfaction, and Landlord may accept
such check in payment without prejudice to Landlord's right to recover the
balance of any sums owed by Tenant hereunder. In the event Landlord bills Tenant
for any charge hereunder and within ninety (90) days of receipt of the same
Tenant does not provide Landlord with notice that it disputes such charge, then
Tenant waives any further right to dispute such charge and that charge shall
automatically become an account stated between Landlord and Tenant.

Security Deposit:

      Tenant, concurrently with the execution of this Lease, shall deposit with
Landlord the sum of Thirteen Thousand Two Hundred and 00/100 Dollars
($13,200.00), which sum shall be held by Landlord as security against a Default
by Tenant, pursuant to the terms of this Lease. The deposit (which shall not
bear interest to Tenant) may be applied by Landlord in order to cure any
Default. The deposit shall be returned to Tenant by the Landlord, after
deducting therefrom any sums owed to Landlord, pursuant to provisions of this
Lease, upon the termination of this Lease, provided such termination is not
caused by Tenant. A mortgagee in possession of the Premises, or any interest
therein, through public or private foreclosure or the acceptance of a deed in
lieu thereof, shall have no liability to Tenant for return of all or any portion
of the deposit, unless, and then only to the extent that, such mortgagee has
acknowledged receipt of all or any portion of Tenant's deposit. In the event
Landlord applies the deposit in whole or in part against a Default by Tenant,
Tenant shall, upon demand by Landlord, deposit sufficient funds to maintain the
deposit in the initial amount. Failure of Tenant to deposit additional funds as
security shall constitute a Default hereunder and entitle Landlord to avail
itself of the remedies as provided in this Lease for non-payment of Minimum Rent
by Tenant. Upon the expiration of the term hereof, Landlord shall retain the
deposit, or so much as has not been applied in accordance with the provisions
hereof, until such time as all of Tenant's obligations to pay any Additional
Rent have been fully paid and satisfied.

Late Charge:

      In the event any sums required hereunder to be paid are not received by
Landlord on or before the date the same are due, then, Tenant shall immediately
pay, as Additional Rent, a service charge equal to the greater of One Hundred
Dollars ($100.00), or ten percent (10%) of the past due sum. In addition,
interest shall accrue on all past due sums at an annual rate equal to the
greater of one and one-half percent (1 1/2%) per month, or three percent (3%) in
excess of the prime rate of interest announced from time to time by Keybank
National Association, or its successor institution, but not in excess of the
maximum legal rate. Such interest shall also be deemed Additional Rent.
Notwithstanding this service and interest charge, Tenant shall be in Default if
all payments required to be made by Tenant are not made at or before the times
herein stipulated. Notwithstanding the foregoing, this Section 2.07 shall be
inapplicable each Lease Year until Landlord shall have provided Tenant with one
(1) written notice of such delinquent payment and a five (5) day opportunity to
cure. Thereafter, no notice shall be required for the remainder of that Lease
Year, regardless of whether Tenant cures within the aforesaid five (5) day cure
period.

Returned Checks:

      In the event that Tenant's check for rents and charges is returned for any
reason, Tenant agrees to pay Landlord the sum of Fifty Dollars ($50.00) as a
handling charge in addition to any applicable late charge. Returned checks must
be redeemed by

--------------------------------------------------------------------------------
                                      101
<PAGE>

cashier's check. In the event more than one check is returned, Tenant agrees to
pay all subsequent rents and charges by cashier's check.

                             PREPARATION OF PREMISES

Landlord's Work:

      Landlord, at its expense, shall construct the Premises substantially in
accordance with the work described in Exhibit "B" ("Landlord's Work"). All other
work done by Landlord at Tenant's request shall be at Tenant's expense and shall
be paid for by Tenant depositing with Landlord, prior to the commencement of
such other work, a sum equal to the cost for such work, as reasonably estimated
by Landlord. Upon completion thereof, appropriate adjustment shall be made
between Landlord and Tenant based upon the actual cost of the work. The opening
by Tenant of Tenant's business in the Premises shall constitute an
acknowledgment by Tenant that Landlord has sufficiently performed all of
Landlord's Work.

Delivery Date:

      Landlord shall give Tenant written notice of not less than ten (10) days
of the date on which Landlord's Work will be substantially completed and the
Premises will be available to Tenant for the performance of Tenant's Work.
Tenant agrees to take physical possession of the Premises and begin its work
under Section 3.03 on the date Landlord tenders possession of the Premises to
Tenant. The date on which the Premises are made available to Tenant shall be the
"Delivery Date", and from and after the Delivery Date Tenant agrees to
diligently perform Tenant's Work to completion. If the Premises are not
delivered to Tenant within twenty-four (24) months from the date of this Lease,
Landlord and Tenant shall have the option, to terminate this Lease upon prior
written notice to the other party and, in such event, this Lease shall
thereafter be null and void and of no further force or effect, and any money or
security deposited hereunder shall be returned to Tenant and thereafter neither
party shall have any further liability to the other, either for damages or
otherwise, by reason of such termination as though this Lease had not been
executed in the first instance. Under no circumstances shall Landlord be liable
to Tenant in damages for any delay in commencing or completing the Premises, or
for a total failure to complete same or for a failure to deliver same.

      Tenant hereby expressly agrees that the entry or occupancy of the Premises
by Tenant or Tenant's agents or contractors prior to the date herein fixed for
the Term Commencement Date shall be governed by and shall be subject to all of
the terms and provisions of this Lease, and Tenant shall observe and perform all
its obligations under this Lease, including, without limitation, its obligation
to pay charges for temporary utilities, insurance, and other charges pursuant to
the provisions of Exhibit "C", but excepting its obligations to pay Minimum
Rent, Common Area Expenses, Taxes, Insurance, and charges for the Fund, from the
date upon which the Premises are made available to Tenant for its work (or from
the date when Tenant commences to perform Tenant's Work, if earlier) until the
Term Commencement Date.

Tenant's Work:

      Other than work done pursuant to Section 3.01, all work is to be performed
by Tenant at its expense ("Tenant's Work") in accordance with Exhibit "C",
attached hereto and made a part hereof and in accordance with the provisions
hereof. All entry into the Premises and work done by Tenant shall be at Tenant's
risk. Tenant shall prepare and submit to Landlord store design and working
drawings of Tenant's Work with respect to the Premises within thirty (30) days
after the date of this Lease. In the event Tenant's plans and specifications, in
the sole judgment of Landlord or Landlord's architect, are incomplete,
inadequate or inconsistent with the terms of this Lease and/or do not conform to
the standards of design, motif, decor and quality established or adopted by
Landlord and/or would tend to create an imbalance with or be incompatible with
adjoining premises, and/or would subject Landlord to additional costs or
expenses in the performance of Landlord's Work, and/or would provide for or
require any installation or work which is or might be unlawful or create an
unsound or dangerous condition or adversely affect the structural soundness of
the Premises or the building of which the same forms a part, and/or would
interfere with the use and enjoyment of any adjoining space in the building in
which the Premises are located, then, in the event Landlord determines that
Landlord and Tenant are unable to agree upon store design drawings and/or
working drawings, Landlord shall have the option, upon ten (10) days' written
notice to Tenant to declare this Lease null and void and of no further force and
effect, in which event this Lease shall terminate. All work performed by Tenant
shall be subject to Landlord's prior written approval and shall be in accordance
with good construction practices, all applicable laws, codes, ordinances,
regulations, and insurance requirements and Landlord's reasonable rules and
regulations. No material deviations from the final plans and specifications,
once approved by Landlord, shall be permitted. Landlord's review of Tenant's
plans and specifications shall not constitute the assumption of any
responsibility by Landlord for their accuracy or sufficiency, and shall in no
event create an express or implied confirmation that Tenant's design and/or
working drawings have been prepared in accordance with the requirements of
applicable laws, codes, ordinances and regulations. Further, Landlord shall have
no responsibility or liability for any loss or damage to any property belonging
to Tenant. Tenant agrees to pay for all the utilities used or consumed in the
Premises by Tenant on and after the Delivery Date. Tenant shall obtain, at
Tenant's sole expense, all certificates and approvals which may be necessary so
that a certificate of occupancy for the Premises may be issued. Copies of all
such certificates shall be delivered to Landlord prior to Tenant commencing
Tenant's Work. Upon the issuance of the

--------------------------------------------------------------------------------
                                      102
<PAGE>

certificate of occupancy, a copy thereof shall be immediately delivered to
Landlord. Except for Landlord's Work, Tenant shall ready the Premises for the
opening of Tenant's business by the Term Commencement Date.

Alterations by Tenant:

      Tenant may not make any exterior, structural or mechanical alterations to
the Premises without the prior written consent of Landlord. In addition, Tenant
shall not make any interior alterations, except for alterations to the decor of
the Premises provided such alterations affect color or merchandising aspects of
the interior only, without giving prior written notice to Landlord and Landlord
giving Tenant its written consent therefore. Any such alterations shall be
performed in a good and workmanlike manner and in accordance with applicable
legal and insurance requirements and the terms and provisions of this Lease.

      In the event that any mechanic's lien is filed against the Premises or
Shopping Center as a result of any work or act of Tenant, Tenant, at its
expense, shall discharge or bond off the same within ten (10) days from the
filing thereof. If Tenant fails to discharge said mechanic's lien, Landlord may
bond or pay without inquiring into the validity of merits of such lien and all
sums so advanced shall be paid to Landlord as Additional Rent.

      Prior to the commencement of any work by Tenant, Tenant shall obtain
public liability and workmen's' compensation insurance to cover every contractor
to be employed by Tenant, and shall deliver duplicate originals of all
certificates of such insurance to Landlord for written approval.

      If, in an emergency, it shall become necessary to make repairs required to
be made by Tenant, Landlord may reenter the Premises and proceed to have such
repairs made and pay the costs thereof. Tenant shall pay Landlord the costs of
such repairs as Additional Rent.

Remodel:

      During the term of this Lease, Tenant agrees to refurbish (carpet, paint,
replace fixtures, etc.) the Premises as needed and required in order to maintain
a first class operation. All such work shall be carried out in accordance with
the provisions of this Lease, including the provisions of this Lease governing
construction of the Premises.

                               CONDUCT OF BUSINESS

Use and Trade Name:

      Tenant shall use and occupy the Premises for the following purpose only,
and for no other purpose whatsoever: A branch bank and financial center.

      If any governmental license or permit shall be required for the proper and
lawful conduct of Tenant's business or other activity carried on in the
Premises, or if a failure to procure such a license or permit might or would in
any way adversely affect Landlord or the Shopping Center, then Tenant, at
Tenant's expense, shall duly procure and thereafter maintain such a license or
permit and submit the same for inspection by Landlord. Tenant, at Tenant's
expense, shall, at all times, comply with the requirements of each such license
or permit.

Operation of Business:-Intentionally deleted

Utilities:

      Tenant, at its expense, shall arrange for and pay all costs of the charges
for all utilities and services provided or used in or at the Premises,
commencing with the Delivery Date and throughout the term of this Lease. Tenant
shall pay directly to the public utility companies the cost of any installation
not included in Landlord's Work of any and all such utility services. In the
event that Landlord supplies or pays for any such utilities, then as Additional
Rent, Tenant shall reimburse Landlord for the same. In the event, for any reason
whatsoever, any particular utility is not separately metered, then, and in that
event, Tenant shall be responsible for its share based upon the formula that
Landlord, in its reasonable discretion, deems appropriate. Tenant agrees to
indemnify and hold harmless Landlord from and against any and all claims arising
from the installation and maintenance of such utility services and from all
costs and charges for utilities consumed on or by the Premises. Landlord shall
not be liable to Tenant for damages or otherwise (i) if any utilities shall
become unavailable from any public utility company, public authority or any
other person or entity supplying or distributing such utility, or (ii) for any
interruption in any utility service (including, but without limitation, any
heating, ventilation or air conditioning) caused by the making of any necessary
repairs or improvements or by any cause beyond Landlord's reasonable control,
and the same shall not constitute a default, termination or an eviction.

--------------------------------------------------------------------------------
                                      103
<PAGE>

      The parties hereto acknowledge that energy shortages in the region in
which the Shopping Center is located may, from time to time, necessitate reduced
or curtailed operation of the Shopping Center and the business conducted by
Tenant in the Premises. Tenant agrees to and shall comply with such rules and
regulations as may be promulgated from time to time by Landlord with respect to
energy consumption, provided that the same apply uniformly to all tenants in the
Shopping Center, and during such periods of time when, in the opinion of
Landlord, energy shortages so dictate, Tenant shall reduce or curtail business
operations in the Premises as shall be directed by Landlord. Compliance with
such rules and regulations and such reduction or curtailment of business
operations shall not constitute a breach of Landlord's covenant of quiet
enjoyment, nor shall the same constitute an actual or constructive eviction of
Tenant, or otherwise invalidate or affect this Lease, and Tenant shall not be
entitled to any diminution, reduction or abatement of rent during periods of
reduction or curtailment of business operations.

Intentionally Deleted

Sign:

      Tenant shall install and maintain a sign affixed to the exterior of the
Premises in a location and size designated by Landlord, subject to the prior
written approval, which shall not be unreasonably withheld, of Landlord.
Notwithstanding Landlord's approval and/or the terms of this Lease, Tenant's
sign shall conform to all applicable legal, quasi-legal (e.g. deed restrictions,
reciprocal easement agreements, and the like), and insurance requirements and
limitations. Tenant shall pay for all costs in connection with such sign and
shall be responsible for the cost of proper installation and removal thereof and
any damage caused to the Shopping Center and/or Premises thereby. In the event
Landlord deems it necessary to remove such sign, then Landlord shall have the
right to do so, provided, however, Landlord shall replace said sign as soon as
practicable at Landlord's sole cost. No additional signs, which can be seen from
the exterior of the Premises, shall be installed or displayed in, on or about
the Premises without the prior written consent of Landlord. Any interior signs
must be tasteful and shall be prepared in a professional manner (not
hand-lettered). Any sign or display visible from the exterior of the Premises
which does not meet the above criteria may be removed at any time by Landlord
without incurring any liability therefore.

Tenant's Warranties:

      Tenant warrants, represents, covenants and agrees to and with Landlord,
that throughout the term hereof it shall: (i) keep the Premises and any platform
or loading dock used by Tenant in a neat and clean condition, (ii) pay, before
delinquent, any and all taxes, assessments and public charges imposed upon
Tenant's business or fixtures, and pay when due all fees of similar nature,
(iii) observe all rules and regulations established by Landlord for tenants in
the Shopping Center, (iv) observe all restrictive covenants of record which are
applicable to the Shopping Center, provided the same do not prohibit Tenant's
permitted use of the Premises, (v) not use the parking areas or sidewalks or any
space outside the Premises for display, sale, storage, or any other similar
undertaking, (vi) not use any advertising medium or sound devices inside the
Premises which may be heard outside the Premises, or permit any objectionable
odors to emanate from the Premises, (vii) keep the Premises sufficiently heated
to prevent freezing of water in pipes and fixtures in and about the Premises,
(viii) keep the temperature within the Premises at such levels as may be
required by any federal, state or local laws, ordinances or regulations, (x)
employ only such labor in the performance of any work in and about the Premises
as will not cause any conflict or controversy with any labor organization
representing trades performing work for Landlord, its contractors or
subcontractors, (xi) not conduct any auction, distress, fire or bankruptcy sale
(whether real or fictitious) or conduct the type of business commonly referred
to as "discount" or "cut-price", (xii) not use or permit the use of any part of
the Premises for the sale, rental, display or operation of amusement,
electronic, video machines, games, cassettes or devices without the prior
written consent of Landlord or allow the sale or offering of any lottery or
raffle tickets or permit any form of games of chance or gambling, in any form,
without such similar consent, (xiii) not allow the operation of any coin
operated or vending machine in the Premises, except in areas reserved solely for
the use of Tenant's employees, (xiv) conduct its sales practices consistent with
the standards and practices generally acceptable in first-class retail shopping
centers, display and sell only first-quality merchandise in the Premises, and
conduct its business in the Premises in a lawful manner and in good faith, (xv)
not do any act tending to injure the reputation of the Shopping Center as
determined by Landlord, and (xvi) not commit or suffer to be committed any waste
upon the Premises, not place a load upon any floor of the Premises which exceeds
the floor load per square foot area which such floor was designated to carry,
and not commit or suffer to be committed any nuisance or other act or thing
which may disturb the quiet enjoyment of any other occupant or tenant of the
Shopping Center.

Legal Requirements:

      Tenant shall at its own expense, comply with all laws, orders, ordinances
and with directions of public officers thereunder, with all applicable Board of
Fire Insurance Underwriters regulations and other requirements and with all
notices from Landlord's mortgagee respecting all matters of occupancy, condition
or maintenance of the Premises, whether such orders or directions shall be
directed to Tenant or Landlord, and Tenant shall hold Landlord harmless from any
and all costs or expenses on account thereof. Tenant shall procure and maintain
all licenses and permits legally necessary for the operation of Tenant's
business and allow Landlord to inspect them on request.

--------------------------------------------------------------------------------
                                      104
<PAGE>

Intentionally Deleted

Hazardous Materials:

      Tenant agrees that it will not use, permit, hold, release or dispose of
any Hazardous Material (defined hereinafter) on, under or at the Premises or the
Shopping Center and that it will not use or permit the use of the Premises or
any other portion of the Shopping Center as a treatment, storage or disposal
(whether permanent or temporary) site for any Hazardous Material, other than De
Minimis Amounts. The term "De Minimis Amounts" shall mean, with respect to any
given level of Hazardous Materials, that such level or quantity of Hazardous
Materials in any given form or combination of forms (i) does not constitute a
violation of any applicable law, and (ii) is customarily employed in, or
associated with, similar shopping centers and operations such as that of Tenant.
Tenant further agrees that it will not cause or allow any asbestos to be
incorporated into any improvements or alterations which it makes or causes to be
made to the Premises. Tenant hereby holds Landlord harmless from and indemnifies
Landlord against any and all losses, liabilities, damages, injuries, costs,
expenses, fines, penalties, and claims of any and every kind whatsoever
(including, without limitation, court costs and attorneys' fees) which at any
time or from time to time may be paid, incurred or suffered by, or asserted
against Landlord for, with respect to, or as a direct or indirect result of (i)
a breach by Tenant of the foregoing covenants, or (ii) to the extent caused or
allowed by Tenant or any agent, contractor, employee, invitee or licensee of
Tenant, the presence on or under, or the escape, seepage, leakage, spillage,
discharge, emission or release from, onto or into the Premises, the Shopping
Center, the atmosphere, or any watercourse, body of water or groundwater, of any
Hazardous Material (including, without limitation, any losses, liabilities,
damages, injuries, costs, expenses or claims asserted or arising under the
Comprehensive Environmental Response, Compensation and Liability Act, any
so-called "Superfund" or "Superlien" law, or any other Federal, state, local or
other statute, law, ordinance, code, rule, regulation, order or decree
regulating, relating to or imposing liability or standards of conduct concerning
any Hazardous Material); and the provisions of and undertakings and
indemnification set out in this paragraph shall survive the termination of this
Lease, and shall continue to be the personal liability, obligation and
indemnification of Tenant, binding upon Tenant, forever, subject to the
applicable statute of limitations. The provisions of the preceding sentence
shall govern and control over any inconsistent provision of this Lease. For
purposes of this Lease, "Hazardous Material" means and includes any hazardous
substance or any pollutant or contaminant defined as such in (or for purposes
of) the Comprehensive Environmental Response, Compensation, and Liability Act,
any so-called "Superfund" or "Superlien" law, the Toxic Substances Control Act,
or any other Federal, state or local statute, law, ordinance, code, rule,
regulation, order or decree regulating, relating to or imposing liability or
standards of conduct concerning, any hazardous, toxic or dangerous waste,
substance or material, as now or at any time hereafter in effect, or any other
hazardous, toxic or dangerous, waste, substance or material.

      The Premises shall not contain any Hazardous Material on the Delivery
Date. If during Tenant's initial construction work in the Premises Tenant shall
discover any Hazardous Material in the Premises which was not caused by Tenant
or Tenant's agents, employees, or contractors, and which was present in the
Premises prior to Tenant first occupying the Premises, then Tenant shall
promptly notify Landlord and Landlord will diligently remove and dispose of such
Hazardous Materials in compliance with all applicable laws and regulations.

Relocation:-Intentionally deleted

                                   COMMON AREA

Definition:

      The term "Common Areas" shall mean the interior and exterior areas and
facilities within the Shopping Center, which are: (i) not leased to a tenant, or
(ii) by nature not leasable to a tenant for the purpose of the sale of
merchandise or the rendition of services to the general public. Common Areas
shall include but shall not be limited to all parking areas and facilities,
roadways, driveways, entrances and exits, truck service ways and tunnels,
utilities, water filtration and treatment facilities, retention ponds or basins
located within or outside the Shopping Center, retaining and exterior walls,
sidewalks, open and enclosed malls, outside courts, landscaped and planted
areas, escalators, stairways, elevators, service corridors, service areas,
loading docks, hallways, public restrooms, community rooms or areas, roofs,
equipment, signs and any special services provided by Landlord for the common or
joint use and benefit of all tenants in the Shopping Center, their employees,
customers and invitees.

Use:

      During the term of this Lease Tenant is granted, subject to Landlord's
reasonable rules and regulations promulgated by Landlord from time to time, the
nonexclusive license to permit its customers and invitees to use the sidewalks,
customer parking areas, the entrance and exit ways designated by Landlord for
access and egress to and from the Premises from a public street or highway.
Notwithstanding anything contained in this Lease to the contrary, Landlord shall
have the right, at any time and from time

--------------------------------------------------------------------------------
                                      105
<PAGE>

to time, without notice to or consent of Tenant, to change the size, location,
elevation and nature of any of the stores in the Shopping Center or of the
Common Areas, or any part thereof, including, without limitation, the right to
locate and/or erect thereon kiosks, structures and other buildings and
improvements of any type. Subject to any easements and restrictions of record
granted or approved by Landlord from time to time, Common Areas shall be subject
to the exclusive control and management of Landlord, and Landlord shall have the
right, at any time and from time to time, to establish, modify, amend and
enforce reasonable rules and regulations with respect to the Common Areas and
the use thereof. Tenant agrees to abide by and conform to such rules and
regulations on notice thereof and to cause its permitted concessionaires,
invitees and licensees and its and their employees and agents to do the same.

Common Area Expenses:

      Landlord agrees to maintain and keep in good service and repair the Common
Areas. The manner in which such areas and facilities shall be maintained,
managed and operated, and the expenditures therefore, shall be at the sole
discretion of Landlord and the use of such areas and facilities shall be subject
to such reasonable rules and regulations as Landlord shall make from time to
time. Starting with the Term Commencement Date and continuing throughout the
entire term of this Lease, Tenant shall pay Landlord, as Additional Rent,
Tenant's proportionate share of the total costs and expenses incurred in
operating, managing, maintaining, repairing, replacing, equipping, lighting, and
providing sanitation and sewer and other services to the Shopping Center
("Common Area Expenses"). Tenant's proportionate share of Common Area Expenses
shall be paid in advance, in equal monthly installments on or before the first
day of each month. The manner in which said payment shall be used shall be
within the sole reasonable discretion and control of Landlord. Common Area
Expenses shall include, but not be limited to, the following costs and expenses:
(i) gas, electricity, water, sewer and other utility charges (including
surcharges) of whatever nature, (ii) building personnel costs, including, but
not limited to, salaries, wages, employment taxes, fringe benefits and other
direct and indirect costs of engineers, superintendents, watchmen, porters and
any other building personnel, (iii) costs of service and maintenance contracts,
including, but not limited to, chillers, boilers, controls, windows, janitorial
and general cleaning, management fees and security services, (iv) all other
maintenance and repair expenses (including those payable by Landlord under
Section 6.01 hereof) and supplies which may be deductible for such calendar year
in computing Federal income tax liability, (v) any other costs and expenses
(i.e. items which are not capital improvements) incurred by Landlord in
operating the Shopping Center, (vi) the cost of any additional services not
provided to the Shopping Center at the Term Commencement Date but thereafter
provided by Landlord in the prudent management of the Shopping Center, (vii) the
cost of any capital improvements which are made by Landlord after completion of
initial construction of the Shopping Center, provided, however, that the cost of
each such capital improvements, together with any financing charges incurred in
connection therewith, shall be amortized and/or depreciated over the useful life
thereof and only that portion thereof attributable to such calendar year shall
be included in the Common Area Expenses for such calendar year, (viii) deposits
into reserve accounts for capital improvements. Common Area Expenses shall not
include (aa) principal payments or interest payments on any mortgages, deeds of
trust or other financing encumbrances, (bb) leasing commissions payable by
Landlord, or (cc) deductions for depreciation of the improvements shown on
Exhibit "A". Tenant's proportionate share of Common Area Expenses shall be
calculated by multiplying Common Area Expenses by a fraction, the numerator
shall be the total square footage of the Premises, and the denominator shall be
the average total gross leased and occupied square footage in the Shopping
Center for the applicable billing period. For the purpose of calculating
Tenant's proportionate share of Common Area Expenses, the total number of square
feet of constructed gross leased and occupied floor area in the Shopping Center
shall never be less than eighty percent (80%) of the total number of square feet
of constructed gross leasable floor area in the Shopping Center. Notwithstanding
the above, in the event Landlord at any time determines that Tenant's
proportionate share of Common Area Expenses exceeds the amount per square foot
of the Premises as set forth in this Section 5.03, then Tenant, following a
request from Landlord, shall commence to pay with the next monthly installment
of rent due an amount sufficient to result in Tenant's paying its full
proportionate share of Common Area Expenses. At the end of each calendar year,
there shall be an adjustment if the amount paid by Tenant is less than Tenant's
proportionate share actually incurred in that year.

                             REPAIRS AND MAINTENANCE

Landlord's Obligations:

      Subject to including the costs thereof in Common Area Expenses, Landlord
shall keep in good repair the sewer and water lines outside the Premises and the
structural supports, inclusive of the roof, of the Premises; provided, however,
if the need of such repair is (a) caused by Tenant or anyone claiming by or
through Tenant, or (b) due to the installation or removal of Tenant's property
(regardless of fault), then, in any such case, Tenant agrees to reimburse
Landlord for all costs and expenses incurred by Landlord with respect to such
repair.

Tenant's Obligations:

      Except as stated in Section 6.01, Tenant, at its expense, shall (i) make
all repairs and replacements and perform all maintenance work that is necessary
in order to keep the Premises and equipment servicing the Premises, excluding,
however, the sprinkler system, and including but not limited to all utilities
and the heating, ventilating and air conditioning unit(s) (Landlord shall

--------------------------------------------------------------------------------
                                      106
<PAGE>

assign any warranty to any such HVAC unit(s) to Tenant), in good order and
repair and in a safe and dry tenantable condition and in compliance with all
regulations, codes and ordinances, (ii) install and maintain such fire
protection devices as may be required by any governmental body or insurance
underwriter for the Shopping Center, (iii) provide trash storage and removal
services regardless of the location of any storage and removal facilities,
except that if Landlord, in its sole discretion, shall provide trash services,
then, in such event, Tenant shall be obligated to use and pay Landlord for the
same as Additional Rent (Tenant's proportionate share of such trash storage and
removal service costs shall be determined, at Landlord's option, either (aa) by
multiplying such trash storage and removal service costs by a fraction, the
numerator shall be the total square footage of the Premises, and the denominator
shall be the average total gross leased and occupied square footage in the
Shopping Center for the applicable billing period, provided said denominator
shall, in no event, be less than eighty percent (80%) of the gross leasable
square footage in the Shopping Center, or (bb) on the basis of a separate
metering or monitoring of Tenant's use of such services or facilities), (iv) the
heating and air conditioning will be serviced in accordance with the
manufacturer's recommendations. Notwithstanding any contrary provision of this
Article VI, Tenant, at its expense, shall make any and all repairs to the
Premises as may be necessitated by any break-in, forcible entry or other
trespass into or upon the Premises, regardless of whether or not such entry and
damage is caused by the negligence or fault of Tenant or occurs during or after
business hours. If Tenant fails, refuses or neglects to properly maintain the
Premises or to commence or complete any of the repairs or replacements required
to be made by Tenant hereunder promptly and adequately after receipt of written
notice, Landlord may, in addition to any other remedy Landlord may have, but
shall not be required to, make or complete said maintenance, repairs or
replacements and Tenant shall pay the cost and expense thereof, plus a charge of
fifteen percent (15%) thereof, to Landlord upon demand as Additional Rent.

                                REAL ESTATE TAXES

Liability:

      Starting with the Term Commencement Date and continuing throughout the
entire term of this Lease, Tenant shall pay Landlord, as Additional Rent,
Tenant's proportionate share of Taxes, as hereinafter defined, for each tax
year. The term "Taxes" means the total of all taxes and assessments, general and
special, ordinary and extraordinary, real and/or personal, foreseen and
unforeseen, including assessments for public improvements and betterments,
assessed, levied or imposed with respect to the land and improvements included
within the Shopping Center, any tax or surcharge of any kind or nature with
respect to the parking areas or the number of parking spaces in the Shopping
Center. For purposes of determining Taxes, the term Shopping Center shall be
deemed to include any land upon which off-site parking facilities, berms,
landscaping, lighting and/or off-site sewer and utility systems (including
drainage and flood control and retention ponds) serving the Shopping Center are
located, with all improvements situated thereon, provided however that once any
such area, or portion thereof, is sold or leased by Landlord thereby removing
such area from the common area of the shopping center, then such area, or
portion thereof, would no longer be so included. The term "Taxes" also includes
all costs reasonably incurred in any proceeding brought by Landlord to reduce
said Taxes. If at any time during the term of this Lease, the present method of
taxation shall be changed so that in lieu of or in addition to the whole or any
part of any Taxes levied, assessed or imposed on real estate and the
improvements thereon or imposed upon any personality used in connection
therewith or upon the collection of rents or other sums due hereunder, there
shall be levied, assessed or imposed on Landlord a capital levy or other tax
directly on the rents received therefrom and/or a franchise tax, assessment,
levy or charge measured by or based, in whole or in part, upon such rents for
the present or any future building or buildings in the Shopping Center, then all
such taxes, assessments, levies or charges, or the part thereof so measured or
based, shall be deemed to be included within the term "Taxes" for the purposes
hereof. Tenant's proportionate share of Taxes shall be calculated by multiplying
Taxes by a fraction, the numerator shall be the total square footage of the
Premises, and the denominator shall be the average total gross leased and
occupied square footage of the Shopping Center for the applicable billing
period. For the purpose of calculating Tenant's proportionate share of Taxes,
the total number of square feet of constructed gross leased and occupied floor
area in the Shopping Center shall never be less than eighty percent (80%) of the
total number of square feet of constructed gross leasable floor area in the
Shopping Center.

Method of Payment:

      Tenant shall pay its proportionate share of such Taxes by the following
method: one-twelfth (1/12) of the Taxes estimated to be due by Landlord shall be
paid each month with Minimum Rent until the end of the first tax year after the
Term Commencement Date; thereafter, the monthly payments shall be based upon the
tax bill for the previous tax year plus any reasonably anticipated increases.
Any adjustments necessary for the amount paid for the previous tax year shall be
debited or credited (as the case may be) in the next monthly installments until
the liability has been extinguished. Notwithstanding the end of the term hereof,
Tenant shall continue to be liable to Landlord for all Taxes incurred by
Landlord for the term of this Lease, and Tenant shall promptly remit to Landlord
any amount due to Landlord upon notice from Landlord to Tenant. Furthermore, in
the event Landlord at any time determines that Tenant's proportionate share of
Taxes exceeds the amount per square foot of the Premises then being charged
Tenant, then Tenant, following a request from Landlord, shall commence to pay
with the next monthly installment of rent due an amount sufficient to result in
Tenant's paying its full proportionate share of Taxes.

--------------------------------------------------------------------------------
                                      107
<PAGE>

                                    INSURANCE

Landlord's Obligations:

      Landlord shall obtain and maintain during the term of this Lease, fire and
extended coverage insurance, insuring against all reasonable perils and
liabilities, for one hundred percent (100%) of the replacement value of the
Shopping Center (excluding the foundation). Landlord may also obtain rent loss
insurance. Such insurance shall be issued by an insurance company licensed to do
business in the jurisdiction in which the Shopping Center is located.

      Landlord shall obtain and maintain during the term of this Lease,
commercial general liability insurance covering the Common Areas, which policy
is to be on an occurrence basis with minimum limits of not less than One Million
Dollars ($1,000,000.00) per occurrence, and with limits of not less than Three
Hundred Thousand Dollars ($300,000.00) with respect to property damage. Landlord
may also obtain an umbrella insurance policy.

Tenant's Contribution Towards Landlord's Insurance:

      Starting with the Term Commencement Date and continuing throughout the
entire term of this Lease, Tenant shall pay to Landlord, as Additional Rent,
Tenant's proportionate share of Landlord's insurance expenses ("Insurance
Charges"). Tenant's proportionate share of Insurance Charges shall be paid in
advance, in equal monthly installments. Tenant's proportionate share of
Insurance Charges shall be calculated by multiplying Insurance Charges by a
fraction, the numerator shall be the total square footage of the Premises, and
the denominator shall be the total gross leased and occupied square footage in
the Shopping Center for the applicable billing period. For the purpose of
calculating Tenant's proportionate share of Insurance Charges, the total number
of square feet of constructed gross leased and occupied floor area in the
Shopping Center shall never be less than eighty percent (80%) of the total
number of square feet of constructed gross leasable floor area in the Shopping
Center. Notwithstanding the above, in the event Landlord at any time determines
that Tenant's proportionate share of Insurance Charges exceeds the amount per
square foot of the Premises as set forth in this Section 8.02, then Tenant,
following a request from Landlord, shall commence to pay with the next monthly
installment of rent due an amount sufficient to result in Tenant's paying its
full proportionate share of Insurance Charges. At the end of each calendar year,
there shall be an adjustment if the amount paid by Tenant is less than Tenant's
proportionate share actually incurred in that year.

Tenant's Obligations:

      Tenant, at Tenant's sole cost and expense, shall obtain and maintain for
the term of this Lease, insurance policies providing the following coverage: (i)
Tenant's fixtures, equipment, furnishings, merchandise and other contents in the
Premises, for the full replacement value of said items regardless of cause or
peril, (ii) one (1) full year Minimum Rent and business income coverage, (iii)
all perils included in the classification "all-risk property insurance coverage"
under insurance industry practices in effect from time to time in the
jurisdiction in which the Shopping Center is located, (iv) plate glass
insurance, (v) commercial general liability insurance naming Landlord, any
mortgagee and master lessor as additional insureds, which policy is to be in the
minimum amount of One Million Dollars ($1,000,000.00) with respect to any one
person, in the minimum amount of One Million Dollars ($1,000,000.00) with
respect to any one accident, and in the minimum amount of Three Hundred Thousand
Dollars ($300,000.00) with respect to property damage, (vi) product liability
insurance for merchandise offered for sale or rental from the Premises,
including (if this Lease covers Premises in which food and/or beverages are sold
and/or consumed) liquor liability coverage (if applicable to Tenant's business)
and coverage for liability arising out of the consumption of food and/or
alcoholic beverages on or obtained at the Premises, of not less than One Million
Dollars ($1,000,000) per occurrence for personal injury and death and property
damage; and (vii) workers' compensation coverage as required by law. The minimum
limits hereinbefore set forth may, at Landlord's option, be increased from time
to time. Tenant shall deliver to Landlord certificates of insurance (Accord 27),
or certified copies of each such policy prior to occupancy of the Premises.
Neither the issuance of any insurance policy required hereunder, nor the minimum
limits specified herein with respect to Tenant's insurance coverage, shall be
deemed to limit or restrict in any way Tenant's liability arising under or out
of this Lease. With respect to each and every one of the insurance policies
herein required to be procured by Tenant, on or before the commencement of
Tenant's Work and before any such insurance policy shall expire, Tenant shall
deliver to Landlord a duplicate original or certified copy of each such policy
or a certificate of the insurer, certifying that such policy has been issued,
providing the coverage required by this Section and containing provisions
specified herein, together with evidence of payment of all applicable premiums.

      The policies described in this Section 8.03 shall: (i) be acceptable to
Landlord in form and content, (ii) contain an express waiver of any right of
subrogation by the insurance company against Landlord, Landlord's agents and
employees, and mortgagees and ground lessors, (iii) contain a provision that it
shall not be canceled and that it shall continue in full force and effect,
unless Landlord has received at least thirty (30) days prior written notice of
such cancellation or termination, and (iv) not be materially changed without at
least thirty (30) days prior written notice to Landlord.

--------------------------------------------------------------------------------
                                      108
<PAGE>

      Tenant shall not permit to be done any act which will invalidate or be in
conflict with Landlord's insurance policies covering the Shopping Center or any
other insurance referred to in this Lease. Tenant will promptly comply with all
rules and regulations relating to such policies. If the acts of Tenant or its
employees or agents shall increase the rate of insurance referred to in this
Lease, then such increases shall be paid by Tenant as Additional Rent.

Covenants to Hold Harmless:

      Landlord and Tenant each hereby release and waive all rights of
subrogation against the other, its officers, directors, employees and agents
from any and all liability for responsibility for any loss or damage to property
covered by valid and collectible fire insurance with standard and extended
coverage endorsement, or required to be carried hereunder, even if such fire or
other casualties shall have been caused by the fault or negligence of the other
party, or anyone for whom such party may be responsible. Tenant agrees to pay
the increased insurance cost, if any, resulting from such release.

      Tenant hereby indemnifies and agrees to save harmless Landlord, Landlord's
officers, directors, employees, and agents, and any mortgagee and master lessor
of the Shopping Center (collectively, "the Protected Parties"), from and against
all claims, losses, liabilities, damages, and expenses (including but not
limited to attorneys' fees) that arise within the Premises or that arise from or
in connection with (i) the possession, use, occupation, management, repairs,
maintenance or control of the Premises, or any portion thereof, and any
sidewalks adjoining same, (ii) any act or omission of Tenant, its employees,
agents, contractors, licensees, or invitees, or (iii) any violation, breach, or
default of this Lease by Tenant. Tenant shall, at its own cost and expense,
defend any and all actions which may be brought against any of the Protected
Parties with respect to the foregoing. Tenant shall pay, satisfy and discharge
any and all judgments, orders and decrees which may be recovered any of the
Protected Parties in connection with the foregoing. This Section 8.04(b) shall
be inapplicable to events caused by the gross negligence or willful misconduct
of Landlord, or Landlord's agents, employees or contractors.

      Tenant and all those claiming by, through or under Tenant shall store
their property in and shall occupy and use the Premises and any improvements
therein and appurtenances thereto and all other portions of the Shopping Center
complex solely at their own risk and Tenant and those claiming by, through or
under Tenant hereby release Landlord, to the full extent permitted by law, from
all claims of every kind, including loss of life, personal or bodily injury,
damage to merchandise, equipment, fixtures or other property, or damage to
business or for business interruption arising directly or indirectly out of or
from or on account of such occupancy and use resulting from any present or
future condition or state of repair thereof, except that the Landlord shall not
be released from own negligent acts or intentional wrongful acts.

      Landlord shall not be responsible or liable at any time to Tenant, or to
those claiming by, through or under Tenant, for any loss of life, bodily or
personal injury, or damage to property or business, or for business
interruption, that may be occasioned by or through the acts, omissions or
negligence of any other persons, or any other tenants or occupants of any
portion of the Shopping Center.

      Landlord shall not be responsible or liable at any time for any defects,
latent or otherwise, in any buildings or improvements in the Shopping Center or
any of the equipment, machinery, utilities, appliances or apparatus therein, nor
shall Landlord be responsible or liable at any time for loss of life, injury or
damage to any person or to any property or business of Tenant, or those claiming
by, through or under Tenant, caused by or resulting from the bursting, breaking,
leaking, running, seeping, overflowing or backing up of water, steam, gas,
sewage, snow or ice in any part of the Premises or caused by or resulting from
acts of God or the elements, or resulting from any defect or negligence in the
occupancy, construction, operation or use of any buildings or improvements in
the Shopping Center, including the Premises, or any of the equipment, fixtures,
machinery, appliances or apparatus therein.

Liability of Landlord to Tenant:

      Except with respect to any damages resulting from the gross negligence or
willful misconduct of Landlord, its agents or employees, Landlord shall not be
liable to Tenant, its agents, employees or customers, for any damage, loss,
compensation, accident or claims whatsoever.

                             DESTRUCTION OF PREMISES

Continuance of Lease:

      In the event the Premises shall be partially or totally destroyed by fire
or other casualty insured under the provisions of Section 8.01 above, so as to
become partially or totally untenantable, then the damage to the Premises shall
be promptly repaired, unless Landlord shall elect not to rebuild or repair as
hereinafter set forth. Except in the case of termination Minimum Rent shall be
abated in proportion to the amount of the Premises rendered untenantable until
so repaired. In no event shall Landlord be required to repair or replace
Tenant's merchandise, trade fixtures, furnishings or equipment. If more than
twenty-five percent (25%) of the

--------------------------------------------------------------------------------
                                      109
<PAGE>

Premises or of the floor area of the Shopping Center shall be damaged or
destroyed by fire or other casualty, then Landlord may elect that the Shopping
Center and/or the Premises, as the case may be, be repaired or rebuilt or, at
its sole discretion, terminate this Lease by giving written notice to Tenant of
its election to so terminate, such notice to be given within ninety (90) days
after the occurrence of such damage or destruction. If Landlord is required or
elects to repair or rebuild the Premises as herein provided, Tenant shall repair
or replace its merchandise, trade fixtures, furnishings and equipment in a
manner and to at least a condition equal to that immediately prior to its damage
or destruction. In the event of such casualty and rebuild or repair of the same
can not with reasonable diligence be completed within two hundred seventy (270)
days after the date of said casualty, then Landlord or Tenant may terminate this
Lease upon written notice to the other party, which notice must be given, if at
all, within thirty (30) days of the date of such casualty.

Reconstruction; Rent Abatement:

      If all or any portion of the Premises is damaged by fire or other casualty
and this Lease is not terminated in accordance with the above provision, then
all insurance proceeds however recovered shall be made available for payment of
the cost of repair, replacing and rebuilding. Landlord shall use the proceeds
from the insurance as set forth herein to repair or rebuild the Premises to its
condition as on the Delivery Date, and Tenant shall, using the proceeds from the
insurance provided for in Section 8.03, repair, restore, replace or rebuild that
portion of the Premises constituting Tenant's Work as defined herein together
with any additional improvements installed by Tenant, such that the Premises
shall be restored to its condition as of immediately prior to the occurrence of
such casualty. All of the aforesaid Tenant's insurance proceeds shall be
deposited in escrow and shall be disbursed as work on repair, replacement or
restoration progresses upon the certification of Landlord's architect that the
balance in the escrow fund is sufficient to pay the estimated costs of
completing the repair and restoration. If Tenant's insurance proceeds shall be
less than Tenant's obligation hereunder, Tenant shall pay the entire excess
cost. Minimum Rent, which is payable hereunder during the existence of such
damage and until such repair or rebuilding is substantially completed by
Landlord, shall be equitably abated. Equitable abatement shall terminate upon
the earlier of the date upon which Tenant commences to use substantially all of
the Premises for business with the public or the date upon which Landlord
substantially completes its repair or rebuilding work and the expiration of a
period equal in duration to the Fixturing Period.

                                  CONDEMNATION

Eminent Domain:

      If twenty-five percent (25%) or more of the Premises shall be taken or
condemned by any competent government authority, then either party may elect to
terminate this Lease by giving notice to the other party not more than sixty
(60) days after the date of which such title shall vest in the authority. If the
parking facilities are reduced below the minimum parking requirements imposed by
the applicable authorities, Landlord or Tenant may elect to terminate this Lease
by giving notice within one hundred twenty (120) days after such taking,
however, in the event of such termination by Tenant then Landlord shall be
afforded a reasonable opportunity to meet code requirements. In the case of any
taking or condemnation, whether or not the term of this Lease shall cease and
terminate, the entire award shall be the property of Landlord; provided,
however, Tenant shall be entitled to any award as may be allowed for fixtures
and other equipment which under the terms of this Lease would not have become
the property of Landlord; further provided, that any such award to Tenant shall
not be in diminution of any award to Landlord.

                   ASSIGNING, SUBLETTING AND ENCUMBERING LEASE

Assigning, Subletting and Encumbering Lease:

      Except for the sale or merger of Tenant with another bank or financial
institution, Tenant shall not without Landlord's prior written consent, which
Landlord may withhold in its sole discretion, (i) assign or otherwise transfer,
or mortgage or otherwise encumber, this Lease or any of its rights hereunder,
(ii) sublet the Premises or any part thereof, or permit the use of the Premises
or any part thereof by any persons other than Tenant or its agents, or (iii)
permit the assignment or other transfer of this Lease or any of Tenant's rights
hereunder by operation of law. Any attempted or purported transfer, assignment,
mortgaging or encumbering of this Lease or any of Tenant's interest hereunder
and any attempted or purported subletting or grant of a right to use or occupy
all or a portion of the Premises in violation of the foregoing sentence shall be
null and void and shall not confer any rights upon any purported transferee,
assignee, mortgagee, sublessee or occupant.

      In the event Tenant desires to assign or transfer this Lease, or sublet
(or permit occupancy or use of) the Premises, or any part thereof, Tenant shall
give Landlord sixty (60) days prior written notice of Tenant's intention to so
assign or transfer or sublet all or any part of the Premises. For sixty (60)
days following receipt of said notice, Landlord shall have the right,
exercisable by sending written notice to Tenant, to (i) refuse to permit such
assignment, sublet or transfer, (ii) terminate this Lease, or (iii) sublet from
Tenant for the balance of the term of this Lease, (aa) all of the Premises in
the event Tenant notified Landlord of its intention to assign or transfer this
Lease, or (bb) only so much of the Premises as Tenant intends to sublet in the
event Tenant notified Landlord of its intention to sublet the Premises or a
portion thereof, at the same rent per square foot Tenant is obligated to pay to
Landlord

--------------------------------------------------------------------------------
                                      110
<PAGE>

hereunder. Tenant may assign or transfer this Lease, or sublet such space if
Tenant has obtained the prior written consent of Landlord. In the event Tenant
is in Default hereunder, Tenant hereby assigns to Landlord the rent due from any
subtenant of Tenant and hereby authorizes each such subtenant to pay said rent
directly to Landlord. The consent by Landlord to any assignment, transfer or
subletting to any party shall not be construed as a waiver or release of Tenant
under the terms of any covenant or obligation under this Lease, nor shall the
collection or acceptance of rent from any such assignee, transferee, subtenant
or occupant constitute a waiver or release of Tenant of any covenant or
obligation contained in this Lease, nor shall any such assignment, transfer or
subletting be construed to relieve Tenant from giving Landlord said sixty (60)
days notice or from obtaining the consent in writing of Landlord to any further
assignment, transfer or subletting.

      In the event Landlord does not exercise its right to have all or a portion
of the Premises, as the case may be, subleased or assigned to it but gives
Tenant its written consent to assign, transfer or sublet all or a portion of the
Premises to a third party, any monthly rent or other payment accruing to Tenant
as the result of any such assignment, transfer, or sublease, including any lump
sum or periodic payment in any manner relating to such assignment, transfer or
sublease, which is in excess of the rent then payable by Tenant under this Lease
shall be paid by Tenant to Landlord monthly as Additional Rent. Landlord may
require a certificate from Tenant specifying the full amount of any such payment
of whatsoever nature.

      Any costs and expenses, including attorneys' fees (which shall include the
cost of any time expended by Landlord's in-house counsel) incurred by Landlord
in connection with any proposed or purported assignment, transfer or sublease
shall be borne by Tenant and shall be payable to Landlord as Additional Rent.

                           SUBORDINATION AND FINANCING

Subordination:

      This Lease and Tenant's tenancy hereunder shall be subject and subordinate
at all times to the lien of any mortgage or deed of trust now or hereafter
placed upon the interest of Landlord and the Premises. Tenant also agrees that
any mortgagee or trustee may elect to have this Lease a prior lien to its
mortgage or deed of trust, and in the event of such election, and upon
notification by such mortgagee or trustee to Tenant to that effect, this Lease
shall be deemed prior in lien to the said mortgage or deed of trust, whether
this Lease is dated prior to or subsequent to the date of said mortgage or deed
of trust. Tenant agrees to execute and deliver such instruments as may be
desired by Landlord or by any mortgagee or trustee subordinating this Lease to
the lien of any present or future mortgage or deed of trust, or as may be
otherwise required to carry out the intent of this Section. In the event that
Tenant is requested to execute any such instrument subordinating this Lease to
the lien of any future mortgage or future deed of trust, then such instrument
shall contain a provision stating that Tenant's rights under this Lease and its
use, possession, and enjoyment of the Premises pursuant to this Lease shall not
be diminished or disturbed provided Tenant is not in default of this Lease.

Attornment:

      If, and so long as this Lease is in full force and effect, then at the
option of the mortgagee: (a) this Lease shall remain in full force,
notwithstanding (i) a default under the mortgage by Landlord, (ii) failure of
Landlord to comply with this Lease, (iii) a defense to which Tenant might be
entitled against Landlord under this Lease, or (iv) any bankruptcy or similar
proceedings with respect to Landlord, (b) if any such mortgagee shall become
possessed of the Premises, Tenant shall be obligated to such mortgagee to pay to
it the rentals and other charges due hereunder and to thereafter comply with all
the terms of this Lease, and (c) if any mortgagee or purchaser, at a private or
public sale shall become possessed of the Premises, Tenant shall, without
charge, attorn to such mortgagee or purchaser as its landlord under this Lease.
Tenant agrees that in the event Landlord is in default under this Lease, any
mortgagee or trustee under a deed of trust of Landlord's interest in the
Premises shall be permitted (but not required) to enter the Premises for the
purpose of correcting or remedying such default, and Tenant agrees to accept
performance by such mortgagee or trustee in lieu of performance by Landlord.
Tenant further agrees that, from and after written notice from Landlord of the
name and address of any mortgagee or trustee, Tenant will deliver notice to any
such mortgagee or trustee of a default by Landlord under the Lease.
Notwithstanding any provision of this Lease, Tenant agrees that no termination
of the Lease or abatement or reduction or rent or any other amounts under this
Lease shall be effective unless and until such mortgagee or trustee has received
notice and fails within thirty (30) days of the date on which Landlord's cure
period expires to cure the default of Landlord in question, or if the default
cannot be cured within said thirty (30) days, fails to commence and diligently
prosecute the cure of such default.

Financing:

      In the event the construction lender, land lessor or the permanent lender
for the Shopping Center requires, as a condition to financing modifications to
this Lease, provided such modifications are reasonable, do not adversely affect
Tenant, do not materially alter the approved working plans and do not increase
the rent and other sums to be paid hereunder, Landlord shall submit to Tenant a
written amendment with such required modifications and if Tenant fails to
execute and return within twenty (20) days thereafter the amendments that have
been submitted, then Landlord shall have the right to terminate this Lease upon
written notice to Tenant.

--------------------------------------------------------------------------------
                                      111
<PAGE>

Estoppel:

      From time to time and upon fifteen (15) days notice, Tenant agrees to
execute and deliver a written acceptance/estoppel certificate confirming that
Tenant has accepted the Premises and such other facts relative to this Lease as
Landlord or any mortgagee of the Shopping Center may request to be confirmed. If
Tenant fails to execute such certificate, Tenant hereby appoints Landlord as its
attorney-in-fact, irrevocably, to execute and deliver such certificate for
Tenant, or Landlord may elect to terminate this Lease.

                                    DEFAULTS

Events of Default:

      If any or more of the following events occur, said event or events shall
hereby be classified as a "Default":

      If Tenant fails to pay Minimum Rent, Percentage Rent, Additional Rent or
any other charges required to be paid by Tenant when same shall become due and
payable, and such failure continues for five (5) days, however, notwithstanding
the foregoing, Tenant shall not be in default unless Tenant shall have received
one (1) prior notice of late payment in that Lease Year, after which no such
notice shall be required for the remainder of that Lease Year;

      If Tenant shall fail to perform or observe any terms and conditions of
this Lease, and such failure shall continue for ten (10) days after written
notice from Landlord (except that such ten (10) day period shall be
automatically extended for such additional period of time as is reasonably
necessary to cure such Default, if such Default cannot be cured within such
period, provided Tenant commences the process of curing the same within said ten
(10) day period and diligently pursues such cure to completion);

      If Tenant refuses to take possession of the Premises at the Delivery Date,
or fails to open its doors for business on the Term Commencement Date as
required herein, vacates the Premises and permits the same to remain unoccupied
and unattended or substantially ceases to carry on its normal activities in the
Premises;

      If Tenant fails to conduct its business for the use and under the
tradename as set forth in Section 4.01, or fails to continuously operate as set
forth in Section 4.02;

      Deleted

      If Tenant, or any guarantor of Tenant's obligations hereunder, shall make
an assignment for the benefit of creditors or file a petition, in any state
court, in bankruptcy, reorganization, composition, or make an application in any
such proceedings for the appointment of a trustee or receiver for all or any
portion of its property;

      If any petition shall be filed under state law against Tenant or any
guarantor of Tenant's obligations hereunder in any bankruptcy, reorganization or
insolvency proceedings, and said proceedings shall not be dismissed or vacated
within thirty (30) days after such petition is filed;

      If a receiver or trustee shall be appointed under state law for Tenant or
any guarantor of Tenant's obligations hereunder, for all or any portion of the
property of either of them, and such receivership or trusteeship shall not be
set aside within thirty (30) days after such appointment;

      If any execution, levy, attachment or other legal process of law shall
occur upon Tenant's goods, fixtures, or interest in the Premises; or,

      If Tenant shall be given two (2) notices of Default within one (1) Lease
Year under Section 13.01(a), (b), (c), or (d) notwithstanding any subsequent
cure of the Default identified in such notices.

Landlord's Remedies:

      Should a Default occur, Landlord may pursue any or all of the following:

      Landlord may terminate this Lease by giving five (5) days written notice
of such termination to Tenant, whereupon this Lease shall automatically cease
and terminate and Tenant shall be immediately obligated to quit the Premises.
Any other notice to quit or notice of Landlord's intention to reenter the
Premises is hereby expressly waived. If Landlord elects to terminate this Lease,
everything contained in this Lease on the part of Landlord to be done and
performed shall cease without prejudice, subject, however,

--------------------------------------------------------------------------------
                                      112
<PAGE>

to the right of Landlord to recover from Tenant all rent and any other sums
accrued up to the time of termination or recovery of possession by Landlord,
whichever is later, plus all other losses or damages to such default, as set
forth in Section 13.02.

      Upon termination of this Lease pursuant to Section 13.02, Landlord may
proceed to recover possession of the Premises under and by virtue of the
provisions of the laws of the jurisdiction in which the Shopping Center is
located, or by such other proceedings, including reentry and possession, as may
be applicable.

      Should this Lease be terminated before the expiration of the term of this
Lease by reason of Default, or if Tenant shall abandon or vacate the Premises
before the expiration or termination of the term of this Lease without having
paid the full rental for the remainder of such term, then at the time of such
termination or abandonment Tenant shall be liable for all damages sustained by
Landlord, including, without limitation, all rent through the remainder of the
term of this Lease, including Minimum Rent, Additional Rent, and Percentage Rent
(equal to the greater of (i) an annual rate of the average annual Percentage
Rent owed by Tenant from the Term Commencement Date through the date of Default,
and (ii) the amount calculated pursuant to Section 4.02(b) of this Lease), and
reasonable attorneys' fees. Furthermore, Landlord shall have the option to relet
the Premises for such rent and upon such terms as are not unreasonable under the
circumstances, and Tenant shall be liable for all damages sustained by Landlord
in reletting or attempting to relet the Premises, including, without limitation,
brokerage fees and expenses of placing the Premises in first class rentable
condition. Landlord, in putting the Premises in good order or preparing the same
for rerental may, at Landlord's option, make such alterations, repairs or
replacements in the Premises as Landlord, in its sole judgment, considers
advisable and necessary for the purpose of reletting the Premises, and the
making of such alterations, repairs or replacements shall not operate or be
construed to release Tenant from liability hereunder as aforesaid. Landlord
shall in no event be liable in any way whatsoever for failure to relet the
Premises, or in the event that the Premises are relet, for failure to collect
the rent under such reletting, and in no event shall Tenant be entitled to
receive the excess, if any, of such net rent collected over the sums payable by
Tenant to Landlord hereunder. In determining Landlord's damages, (aa) all sums
which are past due at the time of the award shall include an interest charge, as
set forth in Section 2.07 of this Lease, from the due date as set forth herein
until the time of the award, (bb) while all sums which would not have accrued at
the time of the award but for Tenant's Default or abandonment or vacating of the
Premises shall be discounted at the rate of five percent (5%) per annum, after
first being reduced by the fair market rental value of the Premises, which sum
shall also be discounted at the rate of five percent (5%) per annum. The word
"award" means a judgment issued or rendered in a proceeding or action to recover
damages from Tenant, or at the time of Tenant's voluntary payment of the same.

      If Tenant shall fail to pay any monthly installment of rent pursuant to
the terms of this Lease, or any Additional Rent due under this Lease, when each
such payment is due, for two (2) consecutive months, or three (3) times in any
period of six (6) consecutive months, then Landlord may, by giving written
notice to Tenant, exercise any of the following options as a condition of
Tenant's curing such Default: (i) declare the rent reserved under this Lease for
the next six (6) months (or at Landlord's option for a lesser period) to be due
and payable within ten (10) days of such notice; or (ii) require an additional
security deposit to be paid to Landlord within ten (10) days of such notice, in
an amount not to exceed six (6) months rent. Landlord may invoke any of the
options provided for herein at any time during which Default remains uncured.

      If Tenant shall be in Default, Landlord shall have the option, upon ten
(10) days written notice to Tenant, to cure said Default for the account of and
at the expense of Tenant. No such notice shall be required for emergency
repairs.

      Any damage or loss of rent sustained by Landlord may be recovered by
Landlord, at Landlord's option, at the time of the reletting, or in separate
actions, from time to time, as said damage shall have been made more easily
ascertainable by successive reletting, or at Landlord's option in a single
proceeding deferred until the expiration of the term of this Lease (in which
event Tenant hereby agrees that the cause of action shall not be deemed to have
accrued until the date of expiration of said term) or in a single proceeding
prior to either the time of reletting or the expiration of the term of this
Lease.

      Nothing contained herein shall prevent the enforcement of any claim
Landlord may have against Tenant for anticipatory breach by Tenant of any of the
covenants or provisions hereof, Landlord shall have the right of injunction and
the right to invoke any remedy allowed at law or in equity as if reentry,
summary proceedings and other remedies were not provided for herein. Mention in
this Lease of any particular remedy shall not preclude Landlord from any other
remedy, in law or in equity. Tenant hereby expressly waives any and all rights
of redemption granted by or under any present or future laws in the event of
Tenant being evicted or dispossessed for any cause, or in the event of Landlord
obtaining possession of the Premises by reason of the violation by Tenant of any
of the covenants and conditions of this Lease or other use.

      Notwithstanding the foregoing, Landlord shall use reasonable efforts to
mitigate any damages it incurs hereunder as a result of Tenant's default under
the terms of this Lease, however, in the event that such mitigation of damages
involves attempting to relet the Premises and there are other vacancies in the
Shopping Center, then Landlord may give preference to reletting those other
vacant spaces.

--------------------------------------------------------------------------------
                                      113
<PAGE>

Additional Remedies and Waivers:

      The rights and remedies of Landlord set forth herein shall be in addition
to any other right and remedy now or hereinafter provided by law and all such
rights and remedies shall be cumulative. No action or inaction by Landlord shall
constitute a waiver of a Default and no waiver of Default shall be effective
unless it is in writing, signed by Landlord.

Default by Landlord:

      Landlord shall in no event be charged with a default hereunder unless
Landlord shall fail to perform or observe any term, condition, covenant or
obligation required to be performed or observed by it under this Lease for a
period of thirty (30) days after written notice thereof from Tenant; provided,
however, that if the term, condition, covenant or obligation to be performed by
Landlord is of such nature that the same cannot reasonably be performed within
such thirty (30) day period, such default shall be deemed to have been cured if
Landlord commences such performance within said thirty (30) day period and
thereafter diligently undertakes to complete the same. Landlord shall be in
default if Landlord has not commenced to cure within thirty days after such
written notice is received from Tenant.

                            BANKRUPTCY OR INSOLVENCY

Tenant's Interest Not Transferable:

      Neither Tenant's interest in this Lease, nor any interest therein of
Tenant nor any estate hereby created in Tenant, shall pass to any trustee or
receiver or assignee for the benefit of creditors or otherwise by operation of
law.

Landlord's Option to Terminate:

      In the event the estate created in Tenant hereby shall be taken, in
execution or by other process of law, or if Tenant or Tenant's Guarantor or
their respective executors, administrators or assigns, if any, shall be
adjudicated insolvent or bankrupt pursuant to the provisions of any state or
federal insolvency or bankruptcy act, or if a receiver or trustee of the
property of Tenant or Tenant's Guarantor, if any, shall be appointed by reason
of the insolvency or inability of Tenant or Tenant's Guarantor, if any, to pay
its debts, or if any assignment shall be made of the property of Tenant or
Tenant's Guarantor, if any, for the benefit of creditors, then and in any such
events, Landlord may at its option terminate this Lease and all rights of Tenant
hereunder, by giving to Tenant notice in writing of the election of Landlord to
so terminate, in which event this Lease shall cease and terminate with the same
force and effect as though the date set forth in said notice were the date
originally set forth herein and fixed for the expiration of the Term, and Tenant
shall vacate and surrender the Premises but shall remain liable as herein
provided.

Tenant's Obligation to Avoid Creditors' Proceedings:

      Tenant or Tenant's Guarantor, if any, shall not cause or give cause for
the institution of legal proceedings seeking to have Tenant or Tenant's
Guarantor, if any, adjudicated bankrupt, reorganized or rearranged under the
bankruptcy laws of the United States, and shall not cause or give cause for the
appointment of a trustee or receiver for the assets of Tenant or Tenant's
Guarantor, if any, and shall not make any assignment for the benefit of
creditors, or become or be adjudicated insolvent. The allowance of any petition
under the bankruptcy law, or the appointment of a trustee or receiver of Tenant
or Tenant's Guarantor, if any, or its assets, shall be conclusive evidence that
Tenant caused, or gave cause therefore, unless such allowance of the petition,
or the appointment of a trustee or receiver, is vacated within thirty (30) days
after such allowance or appointment. Any act described in this Section 14.03
shall be deemed a material breach of Tenant's obligation hereunder, and upon
such breach by Tenant, Landlord may, at its option and in addition to any other
remedy available to Landlord, terminate this Lease and all rights of Tenant
hereunder, by giving to Tenant notice in writing of the election of Landlord to
so terminate.

Application of Bankruptcy Proceeds:

      Notwithstanding anything to the contrary contained in this Article XIV, in
the event, for any reason whatsoever, the interest of Tenant in this Lease is
subject to assignment or sale by the Bankruptcy Court, then, and in that event,
all proceeds of such sale or assignment shall be paid to Landlord and not to
Tenant nor to the bankruptcy estate.

Bankruptcy:

      Neither Tenant's interest in this Lease, nor any estate hereby created in
Tenant nor any interest herein or therein, shall pass to any trustee or receiver
or assignee for the benefit of creditors or otherwise by operation of law,
except as may specifically be provided pursuant to the Bankruptcy Code (11 USC
101 et. seq.), as the same may be amended from time to time.

--------------------------------------------------------------------------------
                                      114
<PAGE>

      Rights and Obligations Under the Bankruptcy Code. (1) It is understood and
agreed that this Lease is a lease of real property in a shopping center as such
lease is described in Section 365 of the Bankruptcy Code, as the same may be
amended from time to time. (2) Upon the filing of a petition by or against
Tenant under the Bankruptcy Code, Tenant, as debtor and as debtor-in-possession,
and any trustee who may be appointed with respect to the assets of or estate in
bankruptcy of Tenant, agree to pay monthly in advance on the first day of each
month, as reasonable compensation for the use and occupancy of the Premises, an
amount equal to all Minimum Rent, Additional Rent and other charges otherwise
due pursuant to this Lease, and to pay Percentage Rent monthly, at the
percentage factor set forth in this Lease for the Lease Year in which such month
falls, on all of the Gross Sales during such month in excess of one-twelfth
(1/12th) of the Break Point for such Lease Year; payment of all such Percentage
Rent to be made by the tenth (10th) day of the succeeding month. (3) Included
within and in addition to any other conditions or obligations imposed upon
Tenant or its successor in the event of the assumption and/or assignment of this
Lease are the following: (i) the cure of any monetary defaults and reimbursement
of pecuniary loss within not more than thirty (30) days of assumption and/or
assignment; (ii) the deposit of an additional sum equal to not less than three
(3) months' Minimum Rent and Additional Rent to be held by Landlord as a
security deposit, which sum shall be determined by Landlord, in its sole
discretion, to be a necessary deposit to secure the future performance under the
Lease of Tenant or its assignee; (iii) the use of the Premises as set forth in
Section 4.01 of this Lease and the quality, quantity and/or lines of
merchandise, goods or services required to be offered for the sale are
unchanged; and (iv) the prior written consent of any mortgagee to which this
Lease has been assigned as collateral security.

                                 RIGHT OF ACCESS

Right of Access:

      Landlord may, upon prior notice to Tenant, enter upon the Premises for the
purpose of inspecting, making repairs, replacements or alterations, and showing
the Premises to prospective purchasers, lenders or lessees. During the last
twelve (12) months of the term, Landlord shall have the right to display one (1)
or more "For Rent" signs on or about the Premises.

                                     DELAYS

Delays:

      If Landlord or Tenant is delayed from performing any of their respective
obligations during the term of this Lease because of acts of God or other cause
beyond their control, then the period of such delays shall be deemed added to
the time herein provided for the performance of any such obligation and the
defaulting party shall not be liable for losses or damages caused by such
delays; provided, however, that this Article shall not apply to the payment of
any sums of money required to be paid by Tenant hereunder or any obligation of
Landlord or Tenant that can be satisfied by the payment of money. Subject to the
foregoing, time is of the essence with respect to all obligations to be
performed by Tenant pursuant to the terms of this Lease.

                                   END OF TERM

Return of Premises:

      Upon the expiration or termination of this Lease, Tenant shall quit and
surrender the Premises to Landlord, in good order, broom clean, normal wear and
tear and acts of God excepted. Subject to the other terms of this Lease, Tenant
shall, at its expense, remove all property of Tenant, all alterations to the
Premises not wanted by Landlord and repair damage caused by such removal and
return the Premises to the condition in which they were prior to the
installation of the article so removed.

Holding Over:

      If Tenant shall hold possession of the Premises after the expiration or
termination of this Lease, at Landlord's option (i) Tenant shall be deemed to be
occupying the Premises as a tenant from month-to-month at double the Minimum
Rent in effect during the last Lease Year immediately preceding such holdover,
plus one-sixth (1/6th) of the average annual Percentage Rent payable hereunder
for the three (3) Lease Years immediately preceding, or the entire portion of
the Lease Term, if less than three (3) Lease Years, and otherwise subject to all
of the terms and conditions of this Lease, or (ii) Landlord may exercise any
other remedies it has under this Lease or at law or in equity including an
action for wrongfully holding over.

                           COVENANT OF QUIET ENJOYMENT

Covenant of Quiet Enjoyment:

      Landlord covenants that if and so long as Tenant pays in full all the rent
and all other charges provided for herein and performs all of its obligations
provided for herein, Tenant shall at all times during the term hereof peaceably
have, hold and enjoy

--------------------------------------------------------------------------------
                                      115
<PAGE>

the Premises, without any interruption or disturbance from Landlord, or anyone
claiming through or under Landlord, subject to the terms hereof, and any
mortgages to which this Lease is subordinate.

                                  MISCELLANEOUS

Interpretation:

      This Lease contains the entire agreement between the parties hereto and
there are no promises, agreements, conditions, undertakings, or warranties or
representations, oral or written, between them other than as herein set forth.

Notice:

      No notice or other communications given under this Lease shall be
effective unless the same is in writing and is delivered in person or mailed by
registered or certified mail, return receipt requested, first class, postage
prepaid, or delivered via over-night courier, addressed: (1) if to Landlord, at
the address set forth on page 1 of this Lease, or to such other address as
Landlord shall designate by giving notice thereof to Tenant, or (2) if to
Tenant, at the address set forth on page 1 of this Lease, or such other address
as Tenant shall designate by giving notice thereof to Landlord. Any such notice,
statement, certificate, request or demand shall, in the case of registered or
certified mailing, be deemed to have been given on the date mailed as aforesaid
in any post office or branch post office regularly maintained by the United
States Government, and in the case of delivery by nationally recognized
overnight courier service, shall be deemed to have been given upon the date of
delivery to an authorized agent of such courier service, except in each case for
notice of change of address or renovation of a prior notice, which shall only be
effective upon receipt.

Applicable Laws:

      It is the intent of the parties hereto that all questions and/or disputes
with respect to the construction of this Lease and the rights and the
liabilities of the parties hereto shall be determined in accordance with the
laws of the State of Indiana. Any and all such disputes shall be filed either in
the courts of Floyd County, Indiana or the court of competent jurisdiction in
the jurisdiction in which the Shopping Center is located. Said choice to be made
in the sole discretion of the party filing suit.

Successors:

      This Lease shall bind and inure to the benefit of the parties hereto and
their respective legal representatives, successors and assigns.

Deleted

Brokers:

      Tenant warrants and represents that there was no broker or agent
instrumental in consummating this Lease. Tenant agrees to indemnify and hold
Landlord harmless against any claims for brokerage or other commission arising
by reason of a breach by Tenant of this representation and warranty. Landlord
shall be responsible for the payment of a broker's fee to Broker, which payment
shall be pursuant to the terms and conditions of a separate written agreement
between Landlord and Broker.

Landlord Assignment:

      Landlord hereunder shall have the right to freely assign this Lease
without notice to or consent of Tenant. In the event of any transfer or
transfers of Landlord's interest in the Premises, including a so-called
sale-leaseback, the transferor shall be automatically relieved of any and all
obligations on the part of Landlord accruing from and after the date of such
transfer, including, but not limited to, any obligation to Tenant with respect
to the security deposit referred to in Section 2.06 of this Lease upon
assignment of the same to the transferee, provided that the interest of the
transferor, as Landlord, in any funds then in the hands of Landlord in which
Tenant has an interest shall be turned over, subject to such interest, to the
then transferee. Upon the termination of any Lease in a sale-leaseback
transaction prior to termination of this Lease, the former lessee thereunder
shall become and remain liable as Landlord hereunder until a further transfer.
No holder of a mortgage or deed of trust to which this Lease is, or may be
subordinate, shall be responsible in connection with the security deposited
hereunder, unless such mortgagee or holder of such deed of trust of lessor shall
have actually received the security deposited hereunder.

Relationship of the Parties:

      The terms of this Lease shall not be interpreted to mean that Landlord and
Tenant are partners or joint ventures.

--------------------------------------------------------------------------------
                                      116
<PAGE>

Waiver of Right of Redemption:

      Tenant hereby expressly waives for itself and all persons claiming by or
through it, any right of redemption or for the restoration of the operation of
this Lease under any present or future law in case Tenant shall be dispossessed
for any cause.

Waiver of Jury Trial:

      Landlord and Tenant hereby waive trial by jury in any action, proceeding
or counterclaim brought by either of the parties hereto against the other on or
in respect of any matter whatsoever arising out of or in any way connected with
this Lease, the relationship of Landlord and Tenant hereunder, Tenant's use or
occupancy of the Premises and/or any claim of injury or damage.

Invalidity of Particular Provisions:

      If any provision of this Lease or the application thereof to any person or
circumstances shall to any extent be invalid or unenforceable, the remainder of
this Lease, or the application of such provision to persons or circumstances
other than those as to which it is invalid or unenforceable, shall not be
affected thereby, and each provision of this Lease shall be valid and be
enforced to the fullest extent permitted by law.

Strict Performance:

      No failure by Landlord to insist upon the strict performance of any term,
covenant, agreement, provision, condition or limitation of this Lease to be
kept, observed or performed by Tenant, and no failure by Landlord to exercise
any right or remedy consequent upon a breach of any such term, covenant,
agreement, provision, condition or limitation of this Lease, shall constitute a
waiver of any such breach or of any such term, covenant, agreement, provision,
condition or limitation.

Tenants' Association:

      In the event that Landlord establishes a tenants' association, media fund,
or advertising or promotion fund (the "Fund") for the benefit of the Shopping
Center and tenants thereof, Tenant shall pay to Landlord, as Additional Rent,
Tenant's proportionate share of any fees or dues required by the Fund. Tenant's
proportionate share of such fees or dues shall be calculated by multiplying all
such fees or dues by a fraction, the numerator shall be the average total square
footage of the Premises, and the denominator shall be the total gross leased and
occupied square footage in the Shopping Center for the applicable billing
period. Said denominator shall, in no event, be less than eighty percent (80%)
of the gross leasable square footage in the Shopping Center. Such payment shall
be paid in advance in equal monthly installments on the first day of each
calendar month without deduction or offset.

Financial Disclosures:

      Tenant and any Guarantor agree promptly to disclose to Landlord any
material adverse change in the financial condition of Tenant or of the Guarantor
occurring from and after the date hereof. Upon Landlord's written request,
Tenant shall promptly furnish to Landlord, from time to time, financial
statements reflecting Tenant's current financial condition, which financial
statements shall be certified as being true and correct by the chief financial
officer and by the chief executive officer of Tenant, and shall upon Landlord's
written request promptly furnish Landlord, from time to time, financial
statements reflecting the current financial condition of each Guarantor of this
Lease, which financial statements shall be certified as being true and correct
by the chief financial officer and by the chief executive officer of each such
Guarantor. Landlord shall use reasonable efforts to keep all financial
information divulged pursuant to this Section 19.14 confidential, however, the
aforesaid confidentiality requirement shall not apply to any information that
becomes generally available to the public, any information received by Landlord
from third parties without breach of any confidentiality agreement with respect
to any such information, any disclosure by Landlord to a bank or a potential
purchaser of the Shopping Center, or pursuant to any court order or any
litigation.

Execution in Counterparts:

      This Lease may be executed in one or more counterparts, any one or all of
which shall constitute but one agreement.

Execution of Lease by Landlord:

      The submission of this document for examination and negotiation does not
constitute an offer to lease, or a reservation of, or an option for, the
Premises, and this document shall be effective and binding only upon the
execution and delivery hereof by both Landlord and Tenant.

--------------------------------------------------------------------------------
                                      117
<PAGE>

Security Agreement:

      Tenant hereby grants to Landlord a security interest in all inventory,
equipment, fixtures, trade fixtures, improvements, and merchandise now or
hereafter located in the Premises, and all proceeds and accounts receivable
therefrom (the "Collateral"), to secure the payment and performance of Tenant's
obligations set forth in this Lease. Tenant hereby appoints Landlord its true
and lawful attorney-in-fact in its name or otherwise to execute and file any
financing statement(s) on behalf of Tenant and to do any and all acts and to
execute and file any and all documents which may be necessary to realize,
perfect, continue, preserve and protect the security interest upon the
Collateral. Upon the occurrence of any Default, Landlord shall be entitled to
exercise all of the rights and remedies of a secured party under the Uniform
Commercial Code. Reasonable attorneys' fees of Landlord in enforcing any right
or exercising any remedy pursuant to this Section 19.17 shall be deemed a part
of the obligation secured hereby. Notwithstanding anything to the contrary
contained herein, Tenant may encumber or grant a security interest or other
interest in any signs, inventory, personal property, trade fixtures, and
equipment (excluding permanent leasehold improvements) which Tenant may install
in the Premises to a bona fide mortgagee, lender or secured creditor, to whose
rights Landlord's interest shall be subordinate.

Effect of Captions:

      The captions or legends in this Lease are inserted for convenient
reference or identification of the particular paragraphs. They are in no way
intended to describe, interpret, define or limit the scope, extent or interest
of this Lease, or any paragraph or provision thereof.

Recording:

      This Lease shall not be recorded. Upon Tenant's request, Landlord shall
execute and deliver a recordable memorandum of lease setting forth the term
hereof, the names and addresses of the parties and such other information as may
be mutually agreeable to Landlord and Tenant.

Confidentiality:

      Tenant covenants to not disclose any part of this Lease to anyone other
than its attorneys, accountants, employees, or lenders who need to know of its
content in order to perform their duties for Tenant. Any other disclosure will
be a Default.

      Landlord and Tenant shall be obligated to act in good faith in the
performance and enforcement of their rights and obligations hereunder, and shall
have an obligation to deal fairly and reasonably with each other, having due
regard for all relevant facts and circumstances.

--------------------------------------------------------------------------------
                                      118
<PAGE>

      IN WITNESS WHEREOF, Landlord and Tenant have caused this Lease Agreement
to be executed effective the day and year first above written.

Signed And Acknowledged
In The Presence Of:

                                            LANDLORD:

                                            JWL PROPERTIES LLC,

                                            a Kentucky Limited Liability Company

                                            By:
____________________________________           _________________________________
Witness Signature

____________________________________
Printed Name                                   Printed Name / Title

                                            DATE: ___________

Signed and Acknowledged
In The Presence Of:

                                            TENANT: COMMUNITY BANK SHARES
                                                     OF INDIANA INC

____________________________________        By:_________________________________
Witness Signature

____________________________________
Printed Name                                   Printed Name / Title

DATE: ______________

--------------------------------------------------------------------------------
                                      119
<PAGE>

                                GUARANTY OF LEASE

      In consideration of and as a material inducement to JWL PROPERTIES, LLC
("Landlord") executing and delivering simultaneously herewith, in reliance upon
this Guaranty that certain Lease Agreement ("Lease") dated _________ ______,
2003, between Landlord and __________________ ("Tenant"), the undersigned
(hereinafter called "Guarantor") hereby unconditionally and absolutely
guarantees unto Landlord, it successors and assigns, the full, prompt and
complete payment by Tenant of any Minimum Rent, Additional Rent and any
additional payments, as these terms may be provided for and used in the Lease
and the prompt, faithful and complete performance and observance by Tenant of
all of the terms, covenants and conditions of the Lease on Tenant's part to be
performed or observed.

      Guarantor does hereby waive notice of any and all defaults on the part of
Tenant, waives acceptance and notice of acceptance of this Guaranty, and waives
all demands for payment or performance. Guarantor agrees that no delay on the
part of Landlord in enforcing any of its rights or remedies or insisting
thereupon, nor any extension of time nor any charges or modifications in or to,
or in connection with the Lease, shall in any way limit, affect or impair the
liability of Guarantor hereunder; and Guarantor hereby expressly consents to and
approves thereof with the same force and effect as though its written consent
had been given to each of such delays, extensions, changes and modifications.

      This Guaranty is independent of and in addition to any security or other
remedies which Landlord has or may have for the performance of any of the
obligations on the part of Tenant. Guarantor agrees that Landlord shall not be
required to resort to any other security or other remedies before proceeding
upon this Guaranty, but that Landlord may proceed hereunder against Guarantor at
any time it sees fit, independently of or concurrently with any other remedies
it may have.

      The undersigned agree that in the event of insolvency, bankruptcy, or
reorganization of Tenant, any liquidation, dissolution, winding-up or
cancellation of the legal status of Tenant, any composition or arrangement by
Tenant with its creditors, and irrespective of any rejection, assignment or
termination of the Lease or any of the terms and conditions thereof by Tenant or
any trustee of Tenant in connection with any petition for bankruptcy or
reorganization filed by Tenant under the Bankruptcy Code or any other applicable
federal or state law, the undersigned shall, nonetheless, remain liable
hereunder for the full and complete performance of the terms and conditions of
the Lease to be complied with or performed by Tenant during the entire Lease
Term designated in the Lease.

      No set-off, counterclaim, reduction or diminution of any obligation, or
any defense of any kind or nature which the Guarantor has or may have against
Landlord shall limit or in any way affect the obligations of the Guarantor
hereunder.

      It is understood that the liability hereunder of Guarantor shall continue
for and during the entire term of the Lease and any renewals or extensions
thereof, notwithstanding any assignment of the Lease or subletting of all or any
portion of the premises demised under the Lease. This Guaranty shall not be
limited to any amount or time and shall at all times include the full
indebtedness and all other liability and obligation of Tenant, or any assignee
or subtenant of Tenant, to Landlord under the Lease.

      If the Guarantor is a corporation and is merged into or with any other
company, firm or corporation, the resulting merged company, firm or corporation
shall become liable as the Guarantor hereunder, to the same extent as the
Guarantor.

      If the Guarantor is a corporation or a partnership (general or limited),
firm or other entity the officers or partners executing this Guaranty on behalf
of Guarantor hereby jointly and severally warrant and represent that the
Guarantor has full power and authority to guarantee the Lease and to make and
execute this Guaranty and that this Guaranty is fully and legally binding upon
Guarantor.

      If this Guaranty is executed by two (2) or more corporation, individuals,
firms, partnerships (general or limited) or other entities (or any combination
thereof) the liability of said parties executing this Guaranty shall be joint
and several.

      Guarantor hereby waives trial by jury in any action, proceeding or
counterclaim brought by Landlord against Guarantor on or in respect of any
matter whatsoever arising out of or in any way connected with the Lease or this
Guaranty, the relationship of Landlord and Tenant hereunder, Tenant's use or
occupancy of the Premises and/or any claim of injury or damage.

      It is the intent of the Guarantor that all questions and/or disputes with
respect to this Guaranty or the Lease and the rights and the liabilities of the
parties thereto shall be determined in accordance with the laws of the State of
Indiana. Any and all such disputes shall be filed either in the courts of Floyd
County, Indiana or the court of competent jurisdiction in the jurisdiction in
which the Shopping Center is located. Said choice to be made in the sole
discretion of the party filing suit.

      This Guaranty shall be binding upon the undersigned, the undersigned's
successors and assigns, and shall inure to the benefit of Landlord, its
successors and assigns and to the benefit of any successor to the interest of
Landlord under the Lease.

Signed And Acknowledged
In The Presence Of:

--------------------------------------------------------------------------------
                                      120
<PAGE>

GUARANTOR:

____________________________________
Witness Signature

____________________________________
Printed Name

                   Acknowledgment of Guarantor, if Corporation

STATE OF ____________________________________________)
                                                     )ss:
COUNTY OF ___________________________________________)

      On this ____ day of ____________, 200__, before me personally came
____________________________, to me personally known, who, being by me duly
sworn, did depose and say that he resides in
________________________________________________, and who acknowledged that he
executed the Guaranty of Lease as Guarantor.

                                            ____________________________________
                                            (Notary Public)

                   Acknowledgment of Guarantor, if Individual

STATE OF ____________________________________________)
                                                     )ss:
COUNTY OF ___________________________________________)

      On this ____ day of ____________, 200__, before me personally came
____________________________, to me personally known, who, being by me duly
sworn, did depose and say that he resides in
_________________________________________________, and who acknowledged that he
executed the Guaranty of Lease as Guarantor.

                                            ____________________________________
                                            (Notary Public)

                   Acknowledgment of Guarantor, if Partnership

STATE OF ____________________________________________)
                                                     )ss:
COUNTY OF ___________________________________________)

      On this ____ day of ____________, 200__, before me personally came
____________________________, to me personally known, who, being by me duly
sworn, did depose and say that he resides in
________________________________________________, and who acknowledged that he
executed the Guaranty of Lease as Guarantor.

                                            ____________________________________
                                            (Notary Public)

--------------------------------------------------------------------------------
                                      121[ * ]
  = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
  BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
  EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
  1934, AS AMENDED.

EXHIBIT 10.51

PARTNERSHIP
AGREEMENT

BETWEEN

VAXGEN,
INC.

AND

THE
CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE

(KAKETSUKEN)

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED.

PARTNERSHIP
AGREEMENT

          THIS
PARTNERSHIP AGREEMENT (the “Agreement”), is entered into as
of 1st December, 2003 (the “Effective Date”) by and between VAXGEN, INC., a Delaware corporation,
having a principal place of business at 1000 Marina Boulevard, Brisbane,
California 94005-1841 (“VaxGen”) and THE
CHEMO-SERO THERAPEUTIC RESEARCH INSTITUTE (KAKETSUKEN), a Japanese
Juridical Foundation having a principal place of business at 1-6-1 Okubo,
Kumamoto-shi, Kumamoto 860-8568, Japan (“Kaketsuken”).  Kaketsuken and VaxGen may be referred to
herein individually as a “Party”
and collectively as the “Parties.”

BACKGROUND

          A.
       VaxGen is a company
engaged in the research, development, production and commercialization of
products for the prevention or treatment of human infectious diseases;

          B.
       Kaketsuken is an
institute engaged in research, development, production and commercialization of
vaccines and other healthcare products for the prevention and treatment of
infectious diseases;

          C.
       Kaketsuken has
exclusive rights to a smallpox vaccine known as “LC16m8” developed by the
former Chiba Institute.

          D.
       Kaketsuken has
initiated manufacture of LC16m8 in its own facilities and is currently engaged
in manufacturing activities that will lead to the validation of such
manufacture at these facilities (such vaccine known as “LC16-Kaketsuken”);

          E.
       VaxGen desires, on
an exclusive basis, to conduct such trials as may be necessary to obtain
marketing approval of LC16m8 in the United States, with the purpose of
achieving the rapid commercialization of LC16m8 in the United States, and also
desires to commercialize the vaccine in certain areas outside the U.S.; 

          F.
       Kaketsuken desires
to make available to VaxGen limited supplies of  LC-16-Kaketsuken to facilitate VaxGen’s program to obtain
regulatory approval in the United States. Kaketsuken also desires to
manufacture and supply bulk LC16-m8 for VaxGen’s use in producing Vaccine
product in such formulation as is required for regulatory approval in the
United States.  Subject to
Section 6.6, Kaketsuken does not allow VaxGen or its agent
or contractor to manufacture bulk LC16-m8 or bulk product derived from LC16; 

          G.
       The Parties have
executed a letter of intent, dated as of January 9th, 2003, and as extended on
May 29th 2003 and September 9th, 2003 with respect to the foregoing;

          H.
       In connection with
the activities described herein, Kaketsuken desires to grant to VaxGen, and
VaxGen desires to obtain, certain license rights of first refusal and of
exclusivity with respect to LC16m8 on the terms and conditions set forth in
this Agreement; and 

1.

          I.       The
Parties desire to work in partnership toward the goal of rapid regulatory
approval and broad commercialization of LC16m8 in the United States, and
potentially elsewhere, as mutually agreed under the provisions of this
Agreement, and to commit their best commercial efforts to such goal, including,
but not limited to, increasing production capacity as necessary. 

          NOW,
THEREFORE, in consideration of the foregoing background and
the mutual covenants and agreements contained herein, the Parties hereby agree
as follows:

ARTICLE
1

DEFINITIONS

          The
following terms, when capitalized, shall have the following meanings (such
meanings to be equally applicable to both the singular and plural forms of the
terms defined) as used in this Agreement:

          1.1     “Affiliate”
means, with respect to a Party, any Person that, directly or indirectly, is
controlled by, controls or is under common control with such Party, but only
for so long as such relationship exists. 
“Control,” as used in this Section 1.1, means having the power to
direct, or cause the direction of, the management and policies of any entity
through ownership of voting securities. 

          1.2     “Asia”
means the countries and territories of the Eurasian land mass and its adjacent
islands, separated from Europe by the Ural mountains, but not including
Australasia. 

          1.3     “BLA”
means a Biologics License Application as defined in the FD&C Act and
applicable regulations and guidelines promulgated thereunder.

          1.4     “Bulk
Product” means the Vaccine in bulk form, prior to
formulation, filling, finishing, packaging and labeling.

          1.5     “Calendar
Year” means the period of time commencing on January 1 of
a given year, and ending on December 31 of such year.

          1.6     “CDC”
means the United States Centers for Disease Control and Prevention.

          1.7     “Chiba”
means the former Chiba Institute owned by the Chiba Prefecture in Japan, the smallpox-related
assets and rights of which were transferred to Kaketsuken. 

          1.8     “Confidential
Information” shall have the meaning set forth in Article
10.

          1.9     “Control”
or “Controlled” means the right to grant a license or
sublicense to intangible property rights (including patent rights, know-how
and/or trade secret information), and the right to provide access to or
cross-reference to regulatory filings, in each case to the extent not in
violation of the terms of any agreement or other arrangement with any Third
Party in existence as of the Effective Date. 

2.

          1.10    “Cost
of Sales” means the Direct Costs incurred by VaxGen, its
Affiliates and sublicensees, whether incurred by VaxGen or its agents in the [ * ] of the Vaccine, and shall
include:  (a) the costs to [ * ]; (b) the costs to [ * ];  (c) the costs to [ * ];
(d) the costs to [ * ]; (e) the
costs [ * ]. 

          1.11    “Development
Expenses” shall have the meaning set forth in Section
8.2(b).

          1.12    “Direct
Costs” means [ * ] incurred in the direct [ * ]
by a Party and/or by its agents at its behest, excluding [ * ].

          1.13    “Europe”
means the countries, territories and islands of Europe west of the Dardanelles,
Black Sea and Ural mountains.  

          1.14    “FDA”
means the United States Food and Drug Administration, or any successor agency.

          1.15    “FD&C
Act” means the United States Federal Food, Drug and
Cosmetics Act, as amended from time to time.

          1.16    “Field”
means the use of the Vaccine for pre or post-exposure inoculation against
smallpox, in any population for which the Vaccine is approved by the FDA, or
other relevant Regulatory Agency.

          1.17    “Finished
Product” means the Vaccine in finished, packaged and
labeled form, and in such formulation as is required in order to obtain
Regulatory Approval in the Territory.

          1.18    “First
Commercial Sale” means the first commercial sale of the
Vaccine in the Territory for use in the Field whether under IND or BLA.

          1.19    “Forecast”
shall have the meaning set forth in Section 6.5.

          1.20    “Good
Manufacturing Practice” or “cGMP” means the then current
standards for the manufacture of biologicals, as set forth in the FD&C Act
and applicable regulations and guidelines promulgated thereunder.

          1.21    “Gross
Sales Revenue” means the sum of [ * ] from persons or entities due to or by reason of the sale,
distribution or use of Finished Product in the Territory.  Sales of Finished Product intended for
resale to Third Parties, and made internally among [ * ] shall not be deemed sales for purposes of calculating “Gross
Sales Revenues” (however the resale by the recipient shall be included in the
calculation of “Gross Sales Revenues”).

          1.22    “IND”
means an Investigational New Drug Application as defined in the FD&C Act
and applicable regulations and guidelines promulgated thereunder.

3.

          1.23    “Information”
means available techniques and data relating to the Vaccine and including (but
not limited to) practices, methods, knowledge, know-how, skill, experience,
test data including pharmacological, toxicological, non-clinical and clinical
test data, analytical and quality control data, marketing, pricing, distribution,
cost, sales and manufacturing data or descriptions.

          1.24    “Invention”
means any patentable invention or discovery. 

          1.25    “Kaketsuken
Know-How” means any Information owned or Controlled by
Kaketsuken either:  (a) as of the Effective
Date; or (b) during the Term of this Agreement, that is useful or necessary in
the clinical development, Regulatory Approval, commercialization, marketing or
manufacture of the Vaccine for use in the Field in the Territory.  

          1.26    “Kaketsuken
Materials” means any Bulk Product, intermediate used in
the production of Bulk Product, or any other biological materials that may be
transferred by Kaketsuken to VaxGen with Kaketsuken’s consent, subject to the
approval of the authority of Chiba Prefecture. 

          1.27    “Kaketsuken
Patents” means any Patents in force now, or coming into
force during the term of this Agreement that are owned or Controlled by
Kaketsuken or its Affiliates that cover the manufacture, use, sale, offer for
sale or importation of the Vaccine in the Field and in the Territory.  

          1.28    “Marketing
Costs” means those Direct Costs incurred by VaxGen in the
marketing, promotion and sale of [ * ]
and shall include, without limitation: (a) the following costs [ * ]; (b) [ * ]; and (c) costs of [ * ], including, without limitation, [ * ].  Marketing Costs shall only be recoverable under this Agreement
pursuant to Section 8.2(d).

          1.29    “Net
Sales” means Gross Sales Revenue less the following
deductions and offsets, but only to the extent such sums are otherwise included
in the computation of Gross Sales Revenue, or are paid or credited by [ * ] and not otherwise reimbursed: 

                     (a)     credits
for free goods, allowances, trade, cash and/or quantity discounts actually
taken by the customer in such amounts as are customary in the trade;

                     (b)     any
tax, excise, or other governmental charges upon or measured by the production,
sales, transportation, delivery or use of said Finished Product contained
therein;

                      (c)     transportation
and insurance charges and discounts other than those described above;

                     (d)     fees
paid to distributors, selling agents, group purchasing organizations, managed
care entities and other non-affiliated Third Parties;

                     (e)     amounts
repaid or credited by reason of rejections, recalls, destruction or returns or
because of rebates or chargebacks; and

4.

                     (f)     taxes
paid by VaxGen or its Affiliates to the United States Government or an
instrumentality thereof under 42 U.S.C. 300 aa-1 et seq.  or other similar legislation, or to a state
of the United States, insuring against liability arising out of the
manufacture, use or sale of Finished Product by VaxGen or its Affiliates.

          1.30    “Operating
Profit” means the profits resulting from commercial sales
of the [ * ] and shall be equal
to:  (a) Net Sales minus (b) the sum of [ * ].

          1.31    “Other
Allowable Expenses” means those direct expenses [ * ] that are specifically
attributable to the commercialization of the [ * ], and shall include, by way of example, and without
limitation:  (i) the [ * ]; (ii) all [ * ] incurred to [ * ]; (iii) [ * ]; and (iv) [ * ].

          1.32    “Patent”
means patents, applications for patent, provisional applications for patent,
and any patents issuing therefrom (including any divisions, continuations,
continued prosecution applications and continuations-in-part thereof), and
reexamination certificates, reissue patents, patent extensions and patent term
restorations.

          1.33    “Person”
means an individual, corporation, partnership trust or unincorporated
organization.

          1.34    “Product
Labeling” means:  (a) the FDA full prescribing information for the Vaccine,
including any required patient information; and (b) all labels and other
written, printed or graphic matter upon any container, wrapper or any package
insert or outsert utilized with or for the Vaccine.

          1.35    Quality
Protocol”means
an agreement that is mutually agreed by the Parties (and appended at Exhibit
C), and that defines and details the cGMP quality and regulatory
responsibilities and authority of VaxGen and Kaketsuken under this
Agreement.   

          1.36    “R&D
Expenses” means the Direct Costs incurred by [ * ], in the conduct [ * ] of the Agreement[ * ].  “R&D Expenses” shall include the [ * ] incurred by [ * ]
in carrying out the functions described in the previous sentence, including [ * ]. Any financial support received
from [ * ] shall be [ * ]. In the event that [ * ].

          1.37    “Regulatory
Agency” means any supranational, national, regional,
state, provincial or local regulatory agency, department, bureau, commission,
council or other governmental entity, responsible for the granting of any
approvals, licenses, registrations or authorizations necessary for the
commercial manufacture, use, storage, importation, export, transport or sale of
the Vaccine in a regulatory jurisdiction.

          1.38    “Regulatory
Approvals” means any approvals (including, but not
limited to, BLA approval, labeling, pricing and reimbursement approvals),
product, biologic and/or establishment licenses, registrations or
authorizations of any federal, state or local regulatory agency, department,
bureau or other governmental entity, necessary for the commercial manufacture,
use, storage, importation, export, transport or sale of the Vaccine in the
Field in such regulatory jurisdiction.

5.

          1.39    “Regulatory
and Manufacturing Development Expenses”means those Direct Costs incurred by
Kaketsuken in supporting VaxGen’s non-clinical studies and human clinical
trials of Vaccine in the Territory, including without limitation: (a) [ * ];
(b) [ * ]; (c) [ * ]; (d) [ * ].

          1.40    “Secondary
Manufacture” or “Secondary Manufacturing” means the
formulation, filling, finishing and packaging of Bulk Product to create
Finished Product.

          1.41    “Specifications”
means those specifications for Bulk Product and Finished Product (as the case
may be) set forth on Exhibit A.  

          1.42    “Steering
Committee” shall have the meaning set forth in Section
2.3.

          1.43    “Term”
means the period commencing on the Effective Date and ending, unless renewed
per Section 16.1, on the tenth anniversary of the date of FDA marketing
approval of the Vaccine.

          1.44    “Territory”
means the United States.

          1.45    “Third
Party” means any entity other than Kaketsuken or VaxGen
and their respective Affiliates.

          1.46    “Transfer
Price” shall have the meaning set forth in Section
8.1(b).

          1.47    “TSE”
means transmissible spongiform encephalopathy. 

          1.48    “United
States” means the United States, its territories and
possessions and the Commonwealth of Puerto Rico.

          1.49    “USDA”
means the United States Department of Agriculture.

          1.50    “Vaccine”
means that certain live, attenuated, cold-adapted smallpox vaccine incorporating
the LC16m8 vaccinia virus strain, developed originally by Chiba. 

          1.51    “VaxGen
Know-How” means any Information owned or Controlled by
VaxGen either:  (a) as of the Effective
Date; or (b) during the term of this Agreement, that is useful or necessary in
the clinical development, Regulatory Approval, commercialization, marketing or
manufacture of the Vaccine for use in the Field in the Territory.  

          1.52    “VaxGen
Patents” means those Patents owned or Controlled, as of
the Effective Date or thereafter, by VaxGen or its Affiliates that cover the
manufacture, use, sale, offer for sale or importation of the Vaccine in the
Field and in the Territory. 

6.

ARTICLE
2

OVERVIEW

          2.1      Purpose.  The purpose of this Agreement is to
establish a collaboration through which the Parties, collectively, shall
manufacture Vaccine, conduct non-clinical and clinical trials, seek FDA
Regulatory Approval and commercialize Vaccine in the United States in an
expeditious manner.  The Parties may also
collaborate with respect to the exchange of information and further licensing
of intellectual property and conducting non-clinical and clinical trials so as
to obtain Regulatory Approval outside of the United States in an effort to
increase the number of people to whom the Vaccine may be
administered.

          2.2      Commercial
Principles.  The
Parties intend that profits earned from commercial sales of the Finished
Product pursuant to the terms of this Agreement shall be shared [ * ].  The Parties hereby agree that they will so order the commercial
arrangements of the collaboration so as to be consistent with this principle.

          2.3      Steering
Committee.  The
Parties intend to facilitate the successful execution of activities under this
Agreement primarily through a steering committee (the “Steering Committee”)
which will have decision making authority with respect to, without limitation, the
development, clinical trials, regulatory filing and commercialization of the
Vaccine for the Territory. The Steering Committee shall be comprised of an
equal number of representatives from each of VaxGen and Kaketsuken.  The Steering Committee shall meet
telephonically or in person quarterly, or more often as the Parties mutually
agree.  The Parties shall use
commercially reasonable efforts and cooperate with one another in carrying out
their respective obligations hereunder. 

ARTICLE
3

LICENSES

          3.1      License
Grant to VaxGen.  

                     (a)     Subject
to the conditions and limitations set forth in this Agreement, Kaketsuken
hereby grants to VaxGen an exclusive license under Kaketsuken Patents,
Kaketsuken Know-How (and Kaketsuken Inventions (pursuant to Section 11.1(b)) to
use, develop, finish, have finished Bulk Product, and use, offer for sale and
sell the Finished Product, in the Territory for use in the Field.  Notwithstanding the foregoing, Kaketsuken
shall retain the exclusive ownership of Kaketsuken Patents, Kaketsuken Know-How
and Kaketsuken Inventions, and Kaketsuken shall retain the exclusive right to
manufacture Bulk Product. 

                     (b)     Kaketsuken
shall not grant to VaxGen the right to grant sublicenses,
except the right to grant a sublicense to offer for sale and sell the
Finished Product in the Territory in the Field with Kaketsuken’s prior written
approval, which shall not be unreasonably withheld. 

          3.2       Rights
of First Refusal: Europe.     Kaketsuken
hereby grants to VaxGen for the Term of this Agreement, a right of first
refusal to acquire an exclusive license to develop and commercialize the
Vaccine in Europe (or any country thereof) for use in the Field (“European
Project”), as set forth in this Section 3.2.

7.

                     (a)     During
the Term and before Kaketsuken grants to a Third Party any
license for the European Project, except [ * ]  related entities, Kaketsuken
shall provide to VaxGen in writing the opportunity to consider whether it is
interested in acquiring the license for the European Project. Kaketsuken
shall provide to VaxGen under a binder of confidentiality information
and data and offer material terms of a license agreement
concerning the European Project. 

                     (b)     VaxGen
shall have [ * ] following
receipt of such information and terms of offer, in which to
inform Kaketsuken in writing that it is so interested and accept the
material terms of offer of the license agreement.

                     (c)     If
VaxGen informs Kaketsuken that it is so interested, the Parties shall
negotiate in good faith for [ * ]
the details of the license agreement in accordance with the material terms
of offer, which shall be set forth in either an executed license agreement
or an executed legally binding letter of intent.

                     (d)     If VaxGen
fails to notify Kaketsuken of its interest in writing within [ * ], or if the Parties fail to
execute a binding agreement or letter of intent within [ * ], Kaketsuken may proceed to develop and commercialise the
European Project with no further accountability to VaxGen for such opportunity.

                     (e)     In the
case under Section 3.2(d) and if Kaketsuken offers an opportunity to a
Third Party to consider a license agreement, Kaketsuken shall not offer
terms objectively more favorable to the Third Party than those last offered to
VaxGen. If and when Kaketsuken and such Third Party negotiate the terms of a
license agreement and in the course of such negotiation the terms of the
agreement vary from those last offered by Kaketsuken to VaxGen in that they are
more favorable to the Third Party, then in such case, prior to entering into
any binding agreement with such Third Party, Kaketsuken shall first provide
VaxGen an opportunity to enter into that same agreement under the same revised
terms. VaxGen shall have [ * ]
following the offer of such opportunity in which to answer in
writing whether or not it would accept the offer of the agreement.

                     (f)     In the
case under Section 3.2(e) and if VaxGen fails to answer within [ * ] to the offer,
Kaketsuken may proceed to develop and commercialise the European Project
with no further accountability to VaxGen for such
opportunity.   

          3.3       Negotiation
Rights:  Other Territories.  For the territories other than those of the Territory,
Europe, Japan and Asia (“Other Territory”), Kaketsuken shall first seek the
possibility of co-commercializing the Vaccine with VaxGen as its partner, if
VaxGen offers conditions which Kaketsuken deems as substantially non-inferior to
those offered by other entities and acceptable for Kaketsuken for
co-commercializing.

8.

          3.4       Grant-back
and Use of [ * ].

                     (a)     Where
VaxGen [ * ], it shall then
provide to Kaketsuken [ * ].  Kaketsuken shall keep all such [ * ] without prior written notice to
VaxGen.  

                     (b)     Notwithstanding
Section 3.4(a), Kaketsuken [ * ]
in its efforts to [ * ], and if
Kaketsuken seeks to [ * ] it may
[ * ].

                     (c)     Notwithstanding
Section 3.4(a), if Kaketsuken wishes to [ * ], Kaketsuken may [ * ],
and may [ * ], provided that
Kaketsuken shall have first [ * ].

                     (d)     If
Kaketsuken [ * ], it shall then
provide to VaxGen [ * ] relevant
to [ * ]. VaxGen shall maintain
all such [ * ]. 

ARTICLE
4

NON-CLINICAL AND CLINICAL DEVELOPMENT

          4.1       Current
Status.  Prior to
the Effective Date, Chiba, and now Kaketsuken, have developed the Vaccine for
commercialization and use in the Field in Japan.  In that regard, Chiba and Kaketsuken have conducted clinical
trials and have filed for and received Regulatory Approval in Japan, and
Kaketsuken is now in possession of the regulatory dossier and other Information
used in connection with such Regulatory Approval.  

          4.2       Development
Roles in the Territory. 
The Parties shall collaborate with respect to the development of the
Vaccine in the Field in the Territory. 
VaxGen shall be solely responsible for [ * ].  Kaketsuken shall be
responsible for [ * ].  Kaketsuken shall also [ * ] upon VaxGen’s request.  In addition, Kaketsuken shall [ * ].  

          4.3       Consent
for Specific Development Program.  VaxGen shall [ * ]. In the event [ * ],
they shall be conducted in the Territory in compliance with all legal and
regulatory requirements of the Territory. 
As sponsor of any clinical trials of the Vaccine in the Territory,
VaxGen shall properly obtain informed consent from those participating as
clinical trial subjects.  Further,
VaxGen shall be solely responsible for disclosure of known risks of the Vaccine
and shall provide appropriate FDA warnings to those dispensing and those
receiving the Vaccine in the Field and the Territory.  Kaketsuken shall provide non-clinical, clinical and regulatory
advice and consultation upon VaxGen’s reasonable request.

          4.4       Regulatory
Applications.  
VaxGen shall be responsible for preparing and filing and shall own the
applications for Regulatory Approval of the Vaccine in the Territory, i.e. the
IND, the BLA and the drug master file, but excluding any files and applications
concerning the drug substance.  VaxGen
will file all such applications in its own name and shall be responsible for
prosecuting such applications. 
Kaketsuken shall file (via VaxGen as an agent if required by the FDA),
the drug substance master file and site information (IND stage) and other files
describing the drug substance if required by the FDA at the BLA stage.  To support VaxGen in its Regulatory Approval
efforts, Kaketsuken shall review and provide corrections to VaxGen’s draft IND,
VaxGen’s IND amendments, drug master file, draft BLA and BLA Supplements as
well as to their equivalents in areas other than the United States where
Kaketsuken licenses VaxGen to seek marketing approval for the Vaccine.  Likewise, VaxGen shall review and provide
corrections to the Kaketsuken drug substance master file and other regulatory
documents to be filed with the FDA or other Regulatory Agencies in areas other
than the US where Kaketsuken licenses VaxGen to seek marketing approval for the
Vaccine.

9.

          4.5       Regulatory
Meetings and Correspondence.  Notwithstanding anything herein to the contrary, VaxGen or its
agent shall have exclusive responsibility for correspondence and for any
official communications with the FDA or any other Regulatory Authority
regarding the Vaccine in the Field in the Territory.

          4.6       Expenses.  VaxGen shall be responsible for [ * ] incurred by [ * ].  Such costs incurred [ * ]
within [ * ] of receiving a
written invoice [ * ]. VaxGen
shall have [ * ] following
receipt of written notification [ * ].  If VaxGen fails to [ * ] within [ * ],
it shall be deemed that [ * ].

ARTICLE 5

MANUFACTURE
AND SUPPLY OF MATERIALS FOR DEVELOPMENT PROGRAM 

          5.1       Supply
of Bulk Product and Finished Product For Development Program.  Kaketsuken shall manufacture and supply to
VaxGen Finished Product or Bulk Product sufficient for VaxGen’s use to conduct
non-clinical studies and clinical trials in the Territory, free of charge.  Such supply shall consist of:

          a)  [ * ], released under Japanese
specifications for animal studies

          b)  [ * ], to support fill/finish process
development

          c)  [ * ] that meets mutually agreed
specifications and was produced under cGMP, for use in clinical trials.

Notwithstanding any other
section, Kaketsuken’s obligation under this Section 5.1 shall be limited to the
manufacture and supply of the materials detailed in Sections 5.1(a)-(c)
above.  In the event VaxGen requires any
amounts of Bulk Product or Finished Product over and above these amounts, the
Parties shall meet and discuss the matter, with the understanding that [ * ].

ARTICLE 6

COMMERCIAL
MANUFACTURE AND SUPPLY

          6.1       General
Rights and Responsibilities of the Parties.

                     
(a)     Kaketsuken
shall have the exclusive right and obligation, using commercially reasonable
efforts, to manufacture and supply VaxGen’s requirements for Bulk Product for
Secondary Manufacture by VaxGen or its subcontractor, for commercial
distribution and sale in the Territory.

10.

                     (b)     VaxGen
shall have the right and obligation to use commercially reasonable efforts to
perform or have performed all Secondary Manufacture of Bulk Product supplied by
Kaketsuken, provided that prior written notice of subcontractors is supplied to
Kaketsuken.  

          6.2       General
Principles.  The
Parties shall closely coordinate their activities hereunder in order to:  (i) minimize the time of the Vaccine’s
production cycle; (ii) minimize the time required to bring the Vaccine to
market; (iii) maintain low production cost; and (iv) comply with cGMP in their
manufacturing efforts.

          6.3       Kaketsuken
Advisory Role. 
Kaketsuken shall:  (i) deliver to
VaxGen all available documentation regarding the manufacturing and quality
control processes used by Kaketsuken in Secondary Manufacture; (ii) provide to
VaxGen reasonable manufacturing expertise, advice and know-how in its
possession and control and consultation services with respect to the
manufacture and supply of the Finished Product; and (iii) transfer to VaxGen
all Kaketsuken Know-How Information or Kaketsuken Materials necessary or useful
to the Secondary Manufacture, in each case in order to effect the general
principles in Section 6.2. 

          6.4       Kaketsuken’s
Production Capacity and Scale-Up.

                     (a)     The
total amount of production of Bulk Product by Kaketsuken less the amount of
Bulk Product used by Kaketsuken for its internal demand shall be considered the
“Capacity Limit”, and the total production amount, the amount of internal
demand and the Capacity Limit of each year shall be mutually decided by the
Parties. Kaketsuken’s obligations to supply VaxGen’s requirements of Bulk
Product are limited to amounts within this Capacity Limit, subject to Section
6.4(b).

                     (b)     In
the event that VaxGen determines that its requirements for Bulk Product exceed
the Capacity Limit, and provided that: 
i) VaxGen delivers to Kaketsuken written notice [ * ] to its requested delivery date of such additional Bulk
Product; and ii) the Parties have exchanged such assurances and put in place
such risk sharing and risk mitigation measures as are consistent with good
business judgment, then Kaketsuken agrees that it shall scale-up production of
the Bulk Product, in an amount to be mutually agreed by the Parties. 

          6.5       Forecasting.  

                     (a)     No
later than [ * ] before delivery
of Bulk Product is needed, VaxGen shall present to Kaketsuken a [ * ] forecast for Bulk Product based
on the anticipated market demand for the Vaccine in the Territory for each
quarter and, on acceptance by Kaketsuken, the forecast shall become an agreed
forecast between the Parties (“Forecast”). 
The Forecast shall be updated [ * ].  The [ * ] of the Forecast will be a firm commitment to purchase Bulk
Product (the “Firm Order”) and projections for the [ * ] of such forecast shall represent VaxGen’s good faith
estimates of future purchase amounts. 
VaxGen agrees to purchase all Bulk Product supplied by Kaketsuken in
accordance with a Firm Order and accepted by VaxGen pursuant to Section 6.10.  

                     (b)     In
the event that VaxGen decreases or cancels a Firm Order for a given quarter,
Kaketsuken shall use commercially reasonable efforts to wind down or reduce any
manufacturing then occurring or planned to produce doses of the applicable Bulk
Product, and VaxGen shall reimburse Kaketsuken for all [ * ] by Kaketsuken in the manufacture and supply of Bulk Product
in fulfilling its obligation to meet the Firm Order.

11.

          6.6       Failure
to Supply.  

                     (a)     In
the event that Kaketsuken reasonably believes that it will fall short of its
obligations to manufacture Bulk Product under a Forecast for a given quarter by
[ * ], it shall give prompt
written notice of such belief to VaxGen. 

                     (b)     In
the event: Kaketsuken fails on [ * ]
in [ * ] to deliver to VaxGen [ * ] of VaxGen’s Firm Order for Bulk
Product for a given quarter (“Supply Disruption”), except when such Supply
Disruption is the result of Force Majeure as defined in Section 18.3; or
Kaketsuken is unable to or declines to scale-up production capacity as agreed
between the Parties in accordance with Section 6.4(b) (and where VaxGen has
supplied the required notice under such Section 6.4(b)) (“Capacity
Shortage”);or if the Parties mutually agree that it is otherwise in their best
interests that VaxGen undertake some or all of the manufacture of Bulk Product
for sale in the Territory the following shall occur:

                               (i)     Kaketsuken
shall use its reasonable[ * ]
best efforts to obtain the requisite consents from Chiba Prefecture, the
Japanese Government and any and all other authorities for technology transfer
of all relevant Information, Kaketsuken Know-How, Kaketsuken Materials and
other technology necessary or useful for the commercial manufacture of Bulk Product
for the Territory, to VaxGen or to its contract manufacturer.

                               (ii)     Kaketsuken
shall, upon VaxGen’s request, and to the extent under Kaketsuken’s Control,
make available to VaxGen or its contract manufacturer for Bulk Product, and
grant the right to use, all relevant Information, Kaketsuken Know-How,
Kaketsuken Materials and other technology necessary or useful to the commercial
manufacture of Bulk Product for the Territory, provided that Kaketsuken
obtained the consents as described in  (i)
above.

                               (iii)     Kaketsuken
shall [ * ]; and

                               (iv)     With
respect to all doses of Vaccine that Kaketsuken is no longer supplying to
VaxGen in Bulk Product form based upon the mutual agreement of the Parties
pursuant to this Section 6.6(b), VaxGen shall not be obligated to pay to
Kaketsuken the Transfer Price set forth in Section 8.1 with respect to such
doses, but instead shall owe to Kaketsuken the amounts set forth in Section
8.3.

          6.7       Facilities.  Kaketsuken agrees to undertake the capital
investment and staffing commitments and to take all other actions necessary to
enable it to meet its manufacturing and supply obligations hereunder, including
the establishment of new facilities or remodeling of existing facilities, and
validating and obtaining licensure for such facility for such manufacture and
supply.  VaxGen agrees to undertake, or
to cause its contract manufacturer to undertake, the capital investment and
staffing commitments and to take all other actions necessary to enable it to
meet its fill/finish Secondary Manufacturing obligations hereunder, including
the establishment of new facilities or remodeling of existing facilities, and
validating and obtaining licensure for such facility for such Secondary
Manufacture.  

12.

          6.8       Specifications.  Kaketsuken shall manufacture and supply Bulk
Product and Finished Product for the specific development program in accordance
with the applicable Specifications. 
Kaketsuken shall manufacture and supply Bulk Product for commercial
supply to VaxGen in accordance with the applicable Specifications, cGMP, and/or
any requirements mutually agreed upon by the Parties, VaxGen Quality Standards
as described in the Quality Protocol, and other relevant governmental laws,
rules and regulations.  VaxGen shall, or
shall cause its Third Party fill/finish contract manufacturer, to conduct all
Secondary Manufacture in accordance with the applicable Specifications, cGMP,
VaxGen Quality Standards as described in a relevant Quality Protocol, as
appropriate, and other relevant governmental laws, rules and regulations in the
Territory.

          6.9       Delivery
and Shipment. 
Kaketsuken shall provide VaxGen with all information needed to enable
VaxGen to obtain import permits, USDA permits and CDC permits for the Bulk
Product and Finished Product. Kaketsuken shall be responsible for labeling and
packaging such Bulk Product and Finished Product consistent with exportation,
importation and carrier guidelines. 
VaxGen shall be responsible for obtaining in a timely fashion the
appropriate importation permits. 
Finished Product and Bulk Product shall be shipped [ * ] site.  Each lot of Bulk Product or Finished Product so received shall be
accompanied by an official certificate of analysis attesting that such lot
meets the relevant Specifications.  Each
lot will be shipped labeled as “Quarantine”, unless Kaketsuken has been
notified in writing, prior to shipment, of an alternative shipment designation
by VaxGen Quality Assurance.  A copy of
the certificate of analysis, as well as other relevant documentation (as
specified in Exhibit C) will be supplied to VaxGen Quality Assurance prior to
shipment. 

          6.10    Acceptance and Rejection.

                     (a)     Any lot of
Finished Product or Bulk Product released to VaxGen by Kaketsuken hereunder
shall be received and accepted by VaxGen subject to inspection, testing by
VaxGen or its designated agent to ensure that such lot meets the applicable
Specifications and complies with the warranties provided in this
Agreement.  VaxGen shall be allowed a
maximum of [ * ] from the date
of receipt of all relevant documents (as set forth in the Quality Protocol),
after being translated into English, or [ * ] after receipt of the lot, which ever is later, (“Inspection Period”)
to provide written notice to Kaketsuken of VaxGen’s acceptance or rejection of
any portion or all of that lot.  If
VaxGen does not deliver such written notice to Kaketsuken by the end of the
Inspection Period, VaxGen shall be deemed to have accepted the shipment.  Kaketsuken shall, as soon as is commercially
feasible and after completion of any corrective actions that are reasonably identified
by a VaxGen quality investigation and accepted by Kaketsuken, replace the
rejected quantity of Vaccine, subject to Section 6.10(b) and Section 6.10(c).

                     (b)     Promptly
following any rejection by VaxGen of a lot of Vaccine based upon reviewing it
against the Specifications and warranties, Kaketsuken can determine whether the
rejected lot conformed to the applicable Specifications and warranties.  If Kaketsuken does not agree with VaxGen on
the test results, the Parties shall select a mutually acceptable independent
laboratory to carry out tests on representative samples from the rejected
portion of the lot for the purposes of determining appropriate payment
liability.  The determination of the
independent laboratory shall be binding on both Parties, and shall determine
VaxGen’s obligations to pay for, or Kaketsuken’s obligations to replace, the
lot in question.  However, VaxGen
Quality Assurance is solely responsible for releasing any lot of Vaccine for
its intended use, as described in the Quality Protocol. 

13.

                     (c)     If it is
determined, either by the Parties’ mutual agreement or by such independent
laboratory, that the rejected lot of Vaccine did not conform to the applicable
Specifications and/or warranties, Kaketsuken shall, as promptly as is
commercially reasonable, replace such rejected lot with a conforming lot as
provided in Section 6.10(a) above.  [ * ] 
Rejected lots shall be disposed of [ * ] in accordance with Kaketsuken’s instructions and VaxGen’s
quality assurance procedures. 

                     (d)     In the
event that VaxGen has paid the Transfer Price to Kaketsuken for Vaccine which
Kaketsuken agrees or the independent laboratory determines does not conform to
the Specifications and warranties, VaxGen shall receive a credit to its account
for such amounts actually paid to Kaketsuken for such non-conforming Vaccine[ * ].

                     (e)     If the
independent laboratory determines that the rejected lot did conform to the
Specifications and warranties[ * ].

ARTICLE 7

REGULATORY
ISSUES

          7.1     Compliance.

                     (a)     Kaketsuken
shall obtain and maintain, and shall require all of its contractors to obtain
and maintain, all necessary permits, registrations and licenses required to
manufacture and supply Bulk Product and/or Finished Product under this
Agreement.  Kaketsuken shall, and shall
require all of its agents to manufacture and handle Bulk Product and/or Finished
Product manufactured and supplied by Kaketsuken hereunder in accordance with
all laws, rules and regulations promulgated by the applicable Regulatory
Agency, and in compliance with cGMP, and/or any requirements mutually agreed
upon by the parties, and the Quality Protocol.

                     (b)     VaxGen, or
its Third Party fill/finish contract manufacturer, shall obtain and maintain
all necessary permits, registrations and licenses required to manufacture
Finished Product under this Agreement. 
VaxGen shall manufacture, and/or require its agents and licensees to
manufacture, Finished Product in accordance with all applicable federal, state
and local laws, government regulations, and in compliance with cGMP.

          7.2     Audits By VaxGen.  VaxGen shall have the right during normal
business hours and upon reasonable notice to Kaketsuken, to inspect and audit
in a reasonable manner Kaketsuken’s manufacturing and other facilities in order
to ensure its compliance with its obligations under Section 7.1(a),
including the inspection and audit of all batch records and lot release records
for all lots of Bulk Product and Finished Product supplied by Kaketsuken
hereunder.  VaxGen will perform such an
audit [ * ] according to VaxGen
vendor qualification procedures. 
VaxGen’s Quality Department retains the right to inspect or audit
Kaketsuken on a “for cause” basis as a result of any product quality
investigation or suspected failure of Kaketsuken to meet its obligations.   VaxGen will notify Kaketsuken of an impending
“for cause” audit in writing and will schedule the audit at the first available
opportunity for VaxGen personnel. 
Kaketsuken shall use commercially reasonable efforts to obtain for
VaxGen substantially similar audit rights from its contractors hereunder.  

14.

          7.3     Regulatory Audits.

                     (a)     Kaketsuken
shall allow, and shall require all of its contractors to allow, representatives
of the FDA and any other Regulatory Agency with jurisdiction over the
manufacture, marketing and distribution of the Product in a relevant territory
to tour and inspect all facilities utilized by Kaketsuken and its contractors
in the manufacture, testing, packaging, storage, and shipment of Vaccine sold
under this Agreement, and shall cooperate with such representatives in every
reasonable manner.  Kaketsuken shall
promptly notify VaxGen of any impending inspection (prior notice) or of the
arrival of FDA representatives, or other Regulatory Agency at Kaketsuken (no
prior notice), and shall allow representatives of VaxGen to be present at the
facilities so inspected.  Kaketsuken
shall provide VaxGen with a copy of any FDA Form 483 notices of adverse
findings, establishment inspection reports (EIRs), regulatory letters (e.g.
Warning Letters) or similar notifications it receives from any other
governmental authority setting forth adverse findings or non-compliance with
any applicable laws, regulations or standards relating to the Vaccine within [ * ] of its own receipt thereof.  Kaketsuken shall also provide VaxGen with a
copy of its proposed written response to such governmental authority before
submission and shall incorporate any changes thereto which VaxGen may
reasonably request.

                     (b)     For
regulatory inspections that are not specifically related to the manufacture,
testing, packaging, storage, or distribution of the Vaccine under this
Agreement, but may impact activities performed pursuant to this agreement,
Kaketsuken will promptly notify VaxGen of the impending inspection.  Kaketsuken will provide, either in a
redacted form or in written summary form, copies of any regulatory notice of
adverse findings.  Where specific
findings may directly impact the quality of the Vaccine supplied under this
Agreement, Kaketsuken will provide VaxGen with a proposed written response
before submission to the authority and shall incorporate any changes thereto
which VaxGen may reasonably request.

          7.4     Quality
Protocol.  As required by
cGMP, VaxGen has sole responsibility for assuring the quality and releasing any
Bulk Product manufactured by Kaketsuken for VaxGen’s use.  The roles and responsibilities of both
Kaketsuken and VaxGen under cGMP are specifically defined in the Quality
Protocol attached at Exhibit C.  The
Quality Protocol has been approved by the responsible Quality and Regulatory
officials of both Kaketsuken and VaxGen. The Parties shall fully comply with
the obligations and responsibilities as set forth in the Quality Protocol.

ARTICLE 8

TRANSFER
PRICE; PROFIT SHARING; OTHER PAYMENTS

          8.1     Transfer
Price.

                     (a)     In
consideration of Kaketsuken’s supply of Bulk Product to VaxGen for commercial
use, VaxGen shall pay Kaketsuken a transfer price.

15.

                     (b)     The
Parties agree that for the Term of this Agreement the transfer price for Bulk
Product shall be [ * ] (the
“Transfer Price”).

                     (c)     The first
Transfer Price for each US-dose equivalent [ * ] of Bulk Product having a titer sufficient to meet US
standards [ * ]  supplied by Kaketsuken to VaxGen hereunder
for commercial use is provisionally set at [ * ] (the “Provisional Transfer Price”), equating to [ * ].

                     (d)     The
Parties understand that [ * ],
and that, as [ * ] it may be
necessary to [ * ].  The Parties agree that [ * ], they will meet and agree in
good faith upon [ * ].

                     (e)     The
Transfer Price shall be subject to an annual adjustment upon each anniversary
of the Effective Date to account for [ * ].   Such adjusted Transfer Price
shall be the Transfer Price for the following calendar year (e.g., an
adjustment in March 2004 is applicable to 2005 calendar rates), subject to
further adjustment on the following anniversary of the Effective Date.

                     (f)     All payments
due under this Section 8.1 shall be made within [ * ] of VaxGen’s receipt of Bulk Product.

                    (g)     At any
time, either Party may request an adjustment to the Transfer Price, based on
reasonable grounds, including without limitation, material changes in the
economic, marketing and regulatory environments or in manufacturing costs that
affect the transactions described in this Agreement.  In such an event, the Parties shall meet and negotiate such new
Transfer Price in good faith, governed by the terms in Section 8.1(b).

          8.2     Profit
Sharing.

                     (a)     During the
Term, for as long as Kaketsuken supplies Bulk Product to VaxGen for commercial
sale, VaxGen and Kaketsuken shall share in all Operating Profit in the ratio: [ * ] VaxGen; [ * ] Kaketsuken.  Within [ * ] of the end of each of the [ * ] and within [ * ] of the end of the [ * ] calendar quarter of each of
VaxGen’s fiscal years following the First Commercial Sale, VaxGen shall report
to Kaketsuken its Gross Sales Revenue and Net Sales derived therefrom and the
basis of calculation of such Net Sales, as well as [ * ] factored into the computation of Operating Profit and
accrued during such quarter with respect to the Vaccine.  VaxGen shall make payment to Kaketsuken of
Kaketsuken’s share of such Operating Profit with each such quarterly report[ * ].  The reports and payments for the [ * ] of each fiscal year may include reconciliations and year-end
adjustments with respect to previous quarters. 

                     (b)     Upon first
commercial sale, the Parties shall mutually agree as to a certain Net Sales
volume target (the “Sales Target”) for sales of the Vaccine for the [ * ].  VaxGen shall recoup its [ * ], and Kaketsuken shall recoup its [ * ] (collectively, “Development Expenses”), up to that date on a
[ * ] over such [ * ] on a per unit basis as a
function of the following:  [ * ]. VaxGen [ * ] incurred after the First Commercial Sale shall be considered
an [ * ] and deducted from Net
Sales to calculate Operating Profit.  In
the event that Kaketsuken has [ * ]
after First Commercial Sale, the Parties shall meet and agree in good faith via
the Steering Committee whether to [ * ].  After the First Commercial Sale, the parties
will meet and agree in good faith upon a revised Sales Target if necessary.

16.

                     (c)     In the
event that Operating Profit as defined in Section 1.30 is [ * ] in a particular quarter[ * ].

                     (d)     In the
event that Operating Profit as defined in Section 1.30) is [ * ] in a particular quarter, costs
attributed to [ * ] during such
quarter and calculated according to GAAP shall be reimbursed to the Parties
from Net Sales in the following order:

                              (i)          First,
[ * ]

                              (ii)        Then,
[ * ]

                              (iii)       Then
[ * ]

                              (iv)        Then
[ * ]

                              (v)         Then,
in equal absolute amounts, each Parties’ [ * ] above until one Party has received the appropriate quarterly
reimbursement. 

                              
(vi)        Any
remaining balance shall be applied to the partial reimbursement of the other
Party’s [ * ], and any
unreimbursed amount remaining shall be carried over to the next quarter and
reimbursed prior to any reimbursement of [ * ] in such quarter.

                     (e)     In any
given quarter, the [ * ]
deduction in calculating Operating Profit shall not exceed [ * ] without the prior approval of
the Steering Committee.

                     (f)     For the
avoidance of doubt, only those [ * ]
directly and specifically related to [ * ] shall be deducted from Net Sales in calculating at Operating Profit
per Section 8.2 (a).

                     (g)     Kaketsuken
shall be responsible for [ * ].

          8.3     Royalty
and Tech Transfer Payments. 
In the event VaxGen or its contract manufacturer manufactures Bulk
Product, VaxGen shall pay to Kaketsuken [ * ]. In such event, VaxGen shall not pay Kaketsuken any Transfer Price
for such Bulk Product, nor share with Kaketsuken any Operating Profit.  VaxGen shall pay Kaketsuken a [ * ] payable upon [ * ] of VaxGen’s or its contract
manufacturer’s manufacturing site, as well as [ * ].

ARTICLE 9

PROMOTION
AND MARKETING; TRADEMARKS

          9.1     VaxGen’s
Sales. VaxGen shall have the exclusive right to
commercialize the Vaccine in the Field in the Territory.  As appropriate, VaxGen may consult
Kaketsuken with respect to the prices for the Vaccine, provided that VaxGen
shall solely determine the pricing of the Vaccine in the Territory.

          9.2     Vaccine
Trademark.  VaxGen shall
consult in good faith with Kaketsuken prior to VaxGen determining what
trademark to use with the Vaccine for sales in the Territory (the “Vaccine
Trademark”).  VaxGen shall register and
maintain registration of the Vaccine Trademark in the Territory, and shall pay
for [ * ].  VaxGen shall determine in its sole
discretion what action, if any, to take in response to the infringement, or
threatened infringement of such trademark.

17.

          9.3     Promotional
Materials.  VaxGen will
provide review copies of promotional materials to Kaketsuken and will take
Kaketsuken’s comments into account during the finalization of such
materials.  After such consultation,
VaxGen will file all sales representative training materials and all written,
printed, graphic, electronic, audio or video matter, including but not limited
to, journal advertisements, sales visual aids, leave items, formulary binders,
reprints, direct mail, direct-to-consumer advertising, internet postings,
broadcast advertisements, and sales reminder aids intended for use or used by
VaxGen in connection with any promotion of the Vaccine in the Territory (“Product
Promotional Materials”) with the FDA. 
VaxGen shall own all right, title and interest in and to the Product
Promotional Materials, including all copyrights appurtenant thereto.

          9.4     Trade
Dress, Logos, and the Like. 
VaxGen shall be the sole owner of all trade dress, logos, slogans,
designs and copyrights specifically developed for or used on or in connection
with the Vaccine in the Territory.

ARTICLE 10

CONFIDENTIAL
INFORMATION

          10.1    Confidential
Information.  Except to
the extent expressly authorized by this Agreement or otherwise agreed in
writing, the Parties agree that the receiving Party shall keep confidential,
and shall not publish or otherwise disclose or use for any purpose other than
as provided for in this Agreement, any Information and other information and
materials furnished to it by the other Party pursuant to this Agreement or any
Information developed during the course of the activities performed hereunder
(collectively, “Confidential Information”), except to the extent that it can be
established by the receiving Party that such Confidential Information:

                     (a)     was
already known to the receiving Party, other than under an obligation of
confidentiality, at the time of disclosure by the other Party, as evidenced by
the prior written records of the receiving Party;

                     (b)     was
generally available to the public or otherwise part of the public domain at the
time of its disclosure to the receiving Party;

                     (c)     became
generally available to the public or otherwise part of the public domain after
its disclosure to the receiving Party, and other than through any act or
omission of the receiving Party in breach of this Agreement; 

                     (d)     was
disclosed to the receiving Party, other than under an obligation of
confidentiality, by a Third Party who had no obligation to the disclosing Party
not to disclose such information to others; or 

                     (e)     was
independently developed by employees of the receiving Party who had no
knowledge of or access to the Confidential Information of the other Party.

18.

          The
non-disclosure and non-use obligations under this Section 10.1 shall terminate
upon the later of:  (i) [ * ] following the expiration or
termination of this Agreement, or (ii) [ * ] from the Effective Date.

          10.2    Authorized
Disclosure.

                     (a)     Each Party
may disclose Confidential Information hereunder to the extent such disclosure
is allowed under Section 10.1.  Each
Party may disclose Confidential Information as is reasonably necessary in
sublicensing its rights, (and, in the case of Kaketsuken, provided that
Kaketsuken first offered VaxGen the opportunity to obtain a license pursuant to
Section 3.2 and Section 3.3 prior to sublicensing such rights), to the extent
such sublicensing is permitted under this Agreement, or in prosecuting or
defending litigation, or in complying with applicable governmental regulations,
provided, however, that if a Party is required by law or regulation to make any
such disclosures of the other Party’s Confidential Information it will, except
where impracticable for necessary disclosures (for example in the event of
medical emergency) give reasonable advance notice to the other Party of such
disclosure requirement (e.g., filings with the Securities and Exchange
Commission and stock markets) and, will use its reasonable efforts to secure
confidential treatment of such Confidential Information required to be disclosed,
unless in the judgment of such disclosing Party’s legal counsel such
Confidential Information is legally required to be fully disclosed.  

                     (b)     In
addition, and with prior notice to the other Party of each Third Party with
whom a confidential disclosure agreement is being entered into, each Party
shall be entitled to disclose, under a binder of confidentiality containing
provisions at least as protective as those of this Article 10, Confidential
Information to any Third Party for the purpose of carrying out the purposes of
this Agreement.  Nothing in this Article
10 shall restrict any Party from using for any purpose in accordance with this
Agreement any Confidential Information independently developed by it during the
course of conducting hereunder, or from using Confidential Information that is
specifically derived from non-clinical or clinical trials to carry out
marketing, sales or professional services support functions as is customary in
the pharmaceutical industry.

          10.3    Publicity.  The Parties agree that the public
announcement of the execution of this Agreement shall be substantially in the
form of the press release to be mutually agreed to by the Parties.  Any other publication, news release or other
public announcement relating to this Agreement or to the performance hereunder,
shall first be reviewed and approved by both Parties, which approval shall not
be unreasonably withheld; provided, however, that any disclosure which is
required by law as advised by the disclosing Party’s counsel may be made
without the prior consent of the other Party, although the other Party shall be
given prompt notice of any such legally required disclosure and to the extent
practicable shall provide the other Party an opportunity to comment on the
proposed disclosure.  In this regard,
the Parties recognize that VaxGen is a publicly-held company, and that VaxGen
will need to provide information regarding the status of the Vaccine to the investment
community from time to time, subject to the procedures set forth in the
preceding sentence.  The Parties
acknowledge that VaxGen will be obligated to file a redacted copy of this
Agreement with the U.S. Securities and Exchange Commission.  

19.

ARTICLE 11

OWNERSHIP
OF INTELLECTUAL PROPERTY AND PATENT RIGHTS

          11.1    Ownership.

                     (a)     Subject to
the licenses granted hereunder, Kaketsuken shall solely own all right, title
and interest in the Kaketsuken Know-How and Kaketsuken Patents, and VaxGen
shall solely own all right, title and interest in the VaxGen Know-How and
VaxGen Patents.  

                     (b)     Kaketsuken
shall own all Inventions and Information discovered, generated, conceived or
reduced to practice solely by one or more employees or consultants of
Kaketsuken during the Term of and pursuant to the Agreement (“Kaketsuken
Inventions”).  Kaketsuken shall also
retain sole ownership and exclusive rights to patent of all Inventions,
improvements or materials that are developed and approved in the Territory
under Article 5 and Article 4.

                     (c)     VaxGen
shall own all Inventions discovered, generated, conceived, or reduced to
practice solely by one or more employees or consultants of VaxGen during the
Term of and pursuant to the Agreement, subject to Section 11.1(b) (‘‘VaxGen
Inventions”).  VaxGen shall [ * ], provided that Kaketsuken
obtains VaxGen’s prior written approval, not to be unreasonably withheld.

                     (d)     Subject to
Section 11.1(b) and (c), Inventions or improvements conceived or reduced to
practice during the Term and pursuant to the Agreement jointly by both Parties
shall be [ * ]. 

          11.2    Patent
Prosecution.   Kaketsuken
shall have the sole right, but not the obligation, to file applications for,
prosecute and maintain the Kaketsuken Patents. 
VaxGen shall have the sole right, but not the obligation, to file
applications for, prosecute and maintain the VaxGen Patents.  VaxGen shall have the first right, but not
the obligation to file applications for, prosecute and maintain patents on
Joint Inventions in the Territory.  In
the event VaxGen chooses not to so file an application, prosecute or maintain a
patent on a Joint Invention, it shall inform Kaketsuken in writing, at which
time Kaketsuken shall have the right to file an application for, prosecute and
maintain the patent on such Joint Inventions. 

          11.3    Enforcement
Rights.

                     (a)     If either
Party learns of any infringement or threatened infringement by a Third Party of
the VaxGen Patents and/or the Kaketsuken Patents, in each case, in the Field
and in the Territory, such Party shall promptly notify the other Party and
shall provide such other Party with all available evidence of such
misappropriation or infringement.

                     (b)     VaxGen
shall have the right, but not the obligation, to institute, prosecute and
control [ * ] any action or
proceeding with respect to infringement of any VaxGen Patents, Joint Patents or
Kaketsuken Patents in the Field and in the Territory, by counsel of its own
choice.  Kaketsuken shall have the right[ * ] to be represented in any such
action by counsel of its own choice.  If
VaxGen fails to bring an action or proceeding or otherwise take appropriate
action in VaxGen’s discretion to abate such infringement in the Field and in
the Territory within a period of

20.

[ * ]
of notice by Kaketsuken to VaxGen requesting such action, Kaketsuken will have
the right, but not the obligation, to bring and control any such infringement
action relating to the VaxGen Patents, Joint Patents or the Kaketsuken Patents
by counsel of its own choice.  VaxGen
will cooperate with Kaketsuken in any such action or proceeding brought by
Kaketsuken against a Third Party, and shall have the right to consult with
Kaketsuken and to participate in and be represented by independent counsel in
such litigation at its own expense.  If
one Party brings any such action or proceeding under this Section 11.3(b), the
other Party agrees to be joined as a party plaintiff to the extent necessary to
prosecute the action or proceeding and to give the first Party reasonable
assistance and authority to file and prosecute the suit.  Any amounts recovered by either Party pursuant
to this Section 11.3(b) shall first be used to reimburse the Parties for any
legal expenses incurred pursuant to such enforcement, and any remaining amounts
shall be paid [ * ] to the
enforcing Party and [ * ] to the
non-enforcing Party. 

                     (c)     The Party
that controls the prosecution of a given action under this Section 11.3 shall
also have the right to control settlement of such action.

          11.4    Defense
and Settlement of Third Party Claims.  If a Third Party asserts that a patent, trade secret, or other intangible
right owned by it is infringed or misappropriated by the manufacture, use,
sale, or offer for sale of the Vaccine in the Field and in the Territory, then
the Parties shall meet and discuss in good faith the Parties’ responsibilities
and strategy for the defense or settlement of such Third Party claim.

ARTICLE 12

REPRESENTATIONS
AND WARRANTIES

          12.1    Mutual
Representations and Warranties. 
Each of the Parties hereby represents and warrants to the other Party as
follows:

                     (a)     such
Party:  (i) is a corporation or
institute duly organized, validly existing and in good standing under the laws
of the state or prefecture in which it is incorporated; (ii) has the corporate
power and authority and the legal right to own and operate its property and
assets, to lease the property and assets it operates under lease, and to carry
on its business as it is now being conducted; and (iii) is in compliance with
all requirements of applicable law, except to the extent that any noncompliance
would not have a material adverse effect on the properties, business, financial
or other condition of such Party and would not materially adversely affect such
Party’s ability to perform its obligations under this Agreement;

                     (b)     this
Agreement is a legal and valid obligation binding upon such Party and
enforceable in accordance with its terms, and the execution, delivery and
performance of the Agreement by such Party does not conflict with any
agreement, instrument or understanding, oral or written, to which it is a Party
or by which it is bound, nor violate any law or regulation of any court,
governmental body or administrative or other agency having jurisdiction over
it.  Each Party expressly represents and
warrants that it has the full power and authority to enter into this Agreement
and to carry out the obligations contemplated hereby;

21.

                     (c)     such Party
has not, and during the term of the Agreement will not, grant any right to any
Third Party relating to its respective Patents and know-how in the Field in the
Territory which would conflict with the rights granted to the other Party
hereunder; and

                     (d)     it has
taken all necessary corporate action on its part to authorize the execution and
delivery of this Agreement.  Each Party
expressly represents and warrants that it owns (in whole or in part) or
Controls all intellectual property that is the subject of the licenses and
rights granted to the other Party herein.

          12.2    Kaketsuken
Representations and Warranties. 
Kaketsuken represents and warrants to VaxGen as follows:

                     (a)     that to
the best of its knowledge as of the Effective Date, the manufacture, use,
importation, offer for sale or sale of the Vaccine as contemplated hereunder
does not infringe any Third Party intellectual property right in the Territory;

                     (b)     that to
the best of its knowledge as of the Effective Date, all and only the true
inventors of the subject matter claimed are named in the Kaketsuken Patents and
all such inventors have irrevocably assigned all their rights and interests
therein to Kaketsuken; 

                     (c)     that with
respect to all regulatory filings to obtain Regulatory Approvals, the data and
information in Kaketsuken’s submissions are and will be, to the best of
Kaketsuken’s knowledge, free from fraud or material falsity, that the data and
information in Kaketsuken’s submissions are and will be accurate and reliable
for purposes of supporting approval of the submissions;

                     (d)     that all
Bulk Product manufactured by Kaketsuken and/or supplied to VaxGen for
commercial sale under this Agreement: 
(a) will conform to the applicable Specifications, cGMP and/or any
requirements mutually agreed upon by the Parties; (b) will not be adulterated
or misbranded within the meaning of any applicable U.S. or other governmental
law, rule, order or regulation; and (c) will comply with all U.S. laws,
regulations, rules, standards, FDA approvals, registrations or permits, and all
other regulatory permits, approvals and licenses applicable to the manufacture
and supply of such Bulk Product;

                     (e)     Finished
Product supplied to VaxGen for clinical and non-clinical purposes under this
Agreement will conform to the applicable Specifications and any requirements
mutually agreed upon by the Parties; and,

                     (f)     that it
has sufficient rights to and interest in the Kaketsuken Materials and the intellectual
property relating to the composition and manufacture of the Vaccine to grant to
VaxGen the rights set forth hereunder without infringing any Third Party
rights.

          12.3    VaxGen’s
Responsibility for Registration.   During the term of the Agreement, VaxGen shall use its Best
Efforts [ * ] in [ * ] and [ * ] in [ * ],
from the date of this Agreement, and shall create and maintain competent and
appropriate number of staff in divisions of regulatory affairs, production,
R&D organization for this purpose. 
In this context, “Best Efforts” means the same level of effort as VaxGen
would make to promote any major vaccine originated or sold by VaxGen, with
competent and appropriate number of staff in the divisions.  VaxGen shall keep Kaketsuken advised of
general market, economic, and regulatory development that may affect the
development and sale of the Vaccine. 

22.

          12.4    Kaketsuken’s Responsibility for Registration.  During the Term of the agreement, Kaketsuken
shall provide appropriate levels of resource to enables it to provide in a
timely fashion other consultation and consents provided for in this Agreement,
and specifically those requested pursuant to Section 4.3.

ARTICLE 13

COMPETITIVE
TRANSACTIONS

          13.1    VaxGen
shall not, for a period of five (5) years after termination of this Agreement,
develop, to file for obtain regulatory approval, sell, commercialize and/or
otherwise deal in the any product having a similar activity to the Vaccine, and
shall not during the term of this Agreement develop, sell, commercialize and/or
otherwise deal in any products which substantially compete with, or adversely
affect, the sales or commercialization of the Vaccine in the Territory or Other
Territory agreed including Europe, without the prior written consent of
Kaketsuken.

          13.2    The restriction
under Section 13.1 shall be waived under the following circumstances:

                     (a)     Termination
of this Agreement by VaxGen for Kaketsuken’s uncured material breach.

                     (b)     A
determination by the FDA that the Vaccine is not approvable in the Territory.

ARTICLE 14

INFORMATION
AND REPORTS

          14.1    Records.  Each Party agrees to keep complete and
accurate records of its other activities carried out pursuant to this
Agreement.  Kaketsuken agrees to
maintain all records according to cGMP requirements and to provide copies of
relevant records, as described in the Quality Protocol, for VaxGen review and approval
(where applicable). VaxGen and Kaketsuken shall disclose and make available to
each other upon written request and free of charge all such records directly
concerning Vaccine in the Field and in Territory at any time during the Term.

          14.2    Complaints.  Each Party shall maintain a record of all
complaints it receives with respect to the Vaccine regardless of whether the
complaint pertains to the use of the Vaccine within or outside of the
Territory.  Each Party shall notify the
other Party of any complaint pertaining to Vaccine quality or with regulatory
implications received by it in sufficient detail and within two (2) business
days after receipt of such complaint.  
The Parties shall investigate and respond to product quality complaints pursuant to the procedures set
forth in the Quality Protocol. 

23.

          14.3    Adverse
Drug Experiences.  To the
extent either Party receives any information regarding adverse drug experiences
related to the use of the Vaccine, whether such use is within or outside of the
Territory, such Party shall promptly provide the other Party with such
information in accordance with: (a) the Vaccine Adverse Event Reporting Form
set forth in Exhibit B; and (b) the Global Drug Safety Agreement as
drafted and agreed to by the Drug Safety/Pharmacovigilance Departments of the
two Parties.

          14.4    Records
of Revenues and Expenses. 
VaxGen will maintain complete and accurate records which are relevant to
revenues, costs, expenses and payments under this Agreement, and such records
shall be open during reasonable business hours for a period of [ * ] from the creation of individual
records for examination at  Kaketsuken’s
expense, and not more often than [ * ]
each Calendar Year, by an independent certified public accountant selected by
Kaketsuken and reasonably acceptable to VaxGen for the sole purpose of
verifying for Kaketsuken the correctness of calculations and classifications of
such revenues, costs, expenses or payments made under this Agreement.  In the absence of material shortfalls [ * ] in any request for reimbursement
resulting from such audit, the accounting expense shall be paid by
Kaketsuken.  If material shortfalls do
result, VaxGen shall bear the accounting expense.  [ * ]  Any records or accounting information
received from VaxGen shall be Confidential Information for purposes of Article
10.  Results of any such audit shall be
provided to both Parties, subject to Article 10. 

ARTICLE 15

INDEMNIFICATION

          15.1    Indemnification
by VaxGen.  Except as set
forth in Section 15.2, VaxGen shall indemnify, defend and hold Kaketsuken and
its directors, officers, employees, agents and Affiliates harmless from and
against any liabilities, damages, costs or expenses, including reasonable
attorneys’ fees (collectively “Liabilities”) which: (a) arise from any claim,
lawsuit or other action by a Third Party caused by the manufacture, storage,
distribution, marketing, sale or use of Bulk Product (furnished to VaxGen) or
Finished Product; or (b) arise from VaxGen’s or it’s Affiliates’ or sublicensees’
negligent or willful acts or omissions; or (c) arise out of, relate to or
result from the breach by VaxGen of any of its representations or warranties
contained within this Agreement . 
VaxGen shall acquire and maintain for the term of this Agreement
adequate clinical trials, product liability insurance, other appropriate
insurance and/or  government
indemnification (to the extent available) to meet its indemnification
obligations hereunder.  VaxGen shall
name Kaketsuken as a co-insured on all such policies.  Kaketsuken shall have the right to review and inspect such
policies and government indemnification arrangements (if any) upon reasonable
written notice.  If VaxGen fails, as
determined objectively, to maintain adequate product liability insurance and
government indemnification (if any), it shall be considered a material breach
of this agreement.

          15.2    Indemnification
by Kaketsuken.  Except as set forth in Section 15.1,
Kaketsuken shall indemnify, defend and hold VaxGen and its directors, officers,
employees, agents and Affiliates harmless from and against any Liabilities
which:  (a) arise from Kaketsuken’s or
it’s Affiliates’ or sublicensees’ negligent or willful acts or omissions; or  (b) which arise out of, relate to or result
from the breach by Kaketsuken of any of its representations or warranties
contained within this Agreement.

24.

          15.3    Indemnification
Procedures.  A Party
which intends to claim indemnification under Section 15.1 or Section 15.2
hereof (the “Indemnitee”) shall promptly notify the other Party (the
“Indemnitor”) in writing of any claim, lawsuit or other action in respect of
which the Indemnitee or any of its directors, officers, employees, agents and
Affiliates intend to claim such indemnification.  The Indemnitee shall permit, and shall cause its directors,
officers, employees, agents and Affiliates to permit, the Indemnitor, at its
discretion, to settle any such claim, lawsuit or other action and agrees to the
complete control of such defense or settlement by the Indemnitor; provided, however, that such settlement
does not adversely affect the Indemnitee’s rights hereunder or impose any
obligations on the Indemnitee in addition to those set forth herein in order
for it to exercise such rights.  No such
claim, lawsuit or other action shall be settled without the prior written
consent of the Indemnitor, and the Indemnitor shall not be responsible for any
legal fees or other costs incurred other than as provided herein.  The Indemnitee, its directors, officers,
employees, agents and Affiliates shall cooperate fully with the Indemnitor and
its legal representatives in the investigation and defense of any claim,
lawsuit or other action covered by the provisions of this Article 15.  The Indemnitee shall have the right, not the
obligation, to be represented by counsel of its own selection and expense.

          15.4    Payment of Damages.

                     (a)     Any
Liability for which an Indemnitor is or may become liable under Section 15.1 or
Section 15.2 shall be paid first from any funds available through the Vaccine
Injury Compensation Program (“VICP”) established pursuant to 42 U.S.C. 300 aa-1
et seq. or other similar state or federal legislation, if applicable.

                     (b)     Any
Liabilities not subject to subsection (a) above shall be the responsibility of
the Indemnitor.

          15.5    Limitation
of Liability.  Except as
expressly provided hereunder, neither Party shall be liable to the other for
indirect, incidental, special or consequential damages arising out of any of
the terms or conditions of this Agreement or with respect to its performance
hereunder, whether or not foreseeable, except where such damages were caused by
gross negligence or willful misconduct of a Party.

ARTICLE 16

TERM
AND TERMINATION

          16.1    Term.  This
Agreement shall commence as of the Effective Date and, unless sooner terminated
as provided herein, shall continue in effect for a period of ten (10) years and
shall be renewable by mutual agreement of the Parties.

          16.2    Termination for Material Breach. 
Subject to the provisions of this Section 16.2, if either Party (the
“Breaching Party”) shall have committed a material breach of this Agreement and
such material breach shall remain uncured and shall be continuing for a period
of [ * ] following receipt of
notice thereof by the other Party (the “Non-Breaching Party”), or if such
breach is not cured during the applicable notice period, because the Breaching
Party fails to make good faith efforts to cure such breach, then the
Non-Breaching Party shall have the right to
terminate this Agreement by written
notice to the Breaching Party.  Any such
notice of alleged material breach shall include a reasonably detailed
description of all relevant facts and circumstances demonstrating, supporting
and/or relating to each such alleged material breach by the other Party.

25.

          16.3    Termination
by VaxGen.  VaxGen may terminate this Agreement in whole or in part
on sixty (60) days written notice, in the event that the FDA does not approve
the Vaccine for commercial sale in the Territory within four (4) years from the
effective date of this agreement.

          16.4    Termination
by Kaketsuken. 
Kaketsuken may terminate this Agreement in whole or in part:

                     (a)     on sixty
(60) days notice if the FDA does not approve the Vaccine for commercial sale in
the Territory within four (4) years from the effective date of this agreement.;

                     (b)     on thirty
(30) days written notice, for VaxGen’s failure to make payments due Kaketsuken
hereunder; or 

                     (c)     on sixty
(60) days written notice, at any time for failure on VaxGen’ part to share
documents and Information as required under this Agreement, which would
constitute a material breach of this Agreement, noting that this Agreement
contains mutual obligations to share Information, and such a failure on
Kaketsuken’s part would also constitute a material breach of the Agreement.   

          16.5    Bankruptcy.  This Agreement may be terminated by
either Party upon at least [ * ]
prior written notice thereof if the other Party becomes insolvent, makes an
assignment for the benefit of creditors, is the subject of proceedings in
voluntary or involuntary bankruptcy instituted on behalf of or against such
Party, or has a receiver or trustee appointed for all or substantially all of
its property, provided that in the case of an involuntary bankruptcy proceeding
such right to terminate shall only become effective if the Party consents to
the involuntary bankruptcy or such proceeding is not dismissed within [ * ] after the filing thereof.   In case of termination by Kaketsuken for
VaxGen’s bankruptcy, Kaketsuken shall recover 
those materials fully owned by Kaketsuken, and may seek recovery of any
money owed to Kaketsuken by VaxGen pursuant to federal United States bankruptcy
code.

          16.6    Effect
of Termination and Expiration.

                     (a)     Upon
expiration of this Agreement [ * ]
by one Party to the other Party under this Agreement shall [ * ]. 
VaxGen shall [ * ].  Kaketsuken shall [ * ].

                     (b)     Upon
Kaketsuken’s termination of this Agreement for VaxGen’s uncured material
breach, [ * ] VaxGen under this
Agreement by Kaketsuken shall [ * ].  VaxGen shall [ * ] to Kaketsuken [ * ].

                     (c)     Upon
VaxGen’s termination of this Agreement for Kaketsuken’s uncured material
breach, [ * ] Kaketsuken under
this Agreement shall [ * ].  VaxGen shall retain ownership of the drug
masterfile, BLA and trademark for the Vaccine. 

26.

                     (d)     For
any termination or expiration of this Agreement, any and all claims and payment
obligations that accrued prior to the date of such termination or expiration
shall survive, and each Party shall, within [ * ] of such termination or expiration, return all of the other
Party’s Confidential Information.  

          16.7    Vaccine Inventory.  Upon termination or
expiration of this Agreement, VaxGen may sell any unsold Finished Product
within [ * ] after termination or
expiration of this Agreement, in which case the terms of this Agreement or such
of them as are relevant shall continue to operate until [ * ] or the [ * ] expires, whichever first occurs. 

          16.8    Surviving Rights.  The following provisions will survive
expiration or termination of this Agreement as follows :  Articles 10, 11, 12, 14, 15, 16, and 17.

ARTCILE 17

DISPUTE RESOLUTION; GOVERNING LAW

          17.1    Disputes.

                     (a)     The
Parties recognize that disputes as to certain matters may from time to time
arise during the term of this Agreement that relate to either Party’s rights
and/or obligations hereunder.  It is the
objective of the Parties to establish procedures to facilitate the resolution
of disputes arising under this Agreement in an expedient manner by mutual
cooperation and without resort to litigation. 
To accomplish this objective, the Parties agree to follow the procedures
set forth in this Article 17 if and when a dispute arises under this Agreement.

                     (b)     Unless
otherwise specifically recited in this Agreement, disputes between the Parties
shall first be discussed by the Steering Committee.  If such a dispute cannot be resolved in [ * ], it shall be referred by written
notice to the respective executive officers of the Parties designated below or
their designees, for attempted resolution by negotiations within [ * ] after such notice is received.  The designated officers are as follows:

                               For
VaxGen:                Chief
Executive Officer of VaxGen, Inc.

                               For
Kaketsuken:           President
of Kaketsuken

                     (c)     In
the event such designated officers are unable to resolve such dispute, within [ * ], either Party shall then be permitted
to submit the dispute to final and binding arbitration conducted in the English
language.  All such disputes,
controversies or differences which may arise between the Parties hereto, out of
or in relation to or in connection with this Agreement shall be finally settled
by arbitration in either Tokyo or Osaka (as shall be mutually agreed), Japan in
accordance with the Commercial Arbitration Rules of the Japan Commercial
Arbitration Association.  The award
rendered by the arbitrator(s) shall be final and binding upon the Parties
hereto.  For purposes of clarification,
the Parties agree neither to initiate nor to reopen any disputed matter in a
court proceeding following arbitration, but may use the assistance of the
courts only to enforce an arbitration award. 
VaxGen and Kaketsuken shall equally share the out-of-pocket costs of
said arbitration, including the fees for the arbitrators, except that VaxGen and
Kaketsuken each shall pay its respective expenses for legal representation and
expert witnesses, if any.  

27.

          17.2    Governing Law.  This Agreement shall be governed by and
interpreted under the laws of the country of Japan. 

ARTICLE 18

MISCELLANEOUS

          18.1    Assignment.  Neither Party may assign its rights or
obligations under this Agreement without the prior written consent of the other
Party, except in connection with a merger, acquisition nor similar
reorganization or the sale of all or substantially all of its assets, or, the
sale or transfer of substantially all of their vaccine business.  This Agreement shall survive any such merger
or reorganization of either Party with or into, or such sale of assets to,
another party and no consent for such merger, reorganization or sale shall be
needed; provided, however, that this Agreement may not be assigned or
transferred to an acquiring corporation which has a product that competes
directly in the Field with the Vaccine, consistent with the provisions of
Section 13.1; and further provided, that in the event of such merger,
reorganization or sale, no intellectual property rights of the acquiring
corporation shall be included in the technology licensed hereunder.

          This
Agreement shall be binding upon and inure to the benefit of the successors and
permitted assigns of the Parties.  Any
assignment not in accordance with this Agreement shall be void.

          18.2    Consents Not Unreasonably Withheld or
Delayed. 
Whenever provision is made in this Agreement for either Party to secure
the consent or approval of the other, that consent or approval shall not
unreasonably be withheld or delayed, unless specifically otherwise provided.

          18.3    Force Majeure.  Neither Party shall lose any rights
hereunder or be liable to the other Party for damages or losses on account of
failure of performance by the defaulting Party if the failure is occasioned by
government action, war, fire, explosion, acts of terrorism, flood, strike, lockout,
embargo, act of God, or any other similar cause beyond the control of the
defaulting Party, provided that the Party claiming force majeure has exerted
all reasonable efforts to avoid or remedy such force majeure and has given the
other Party prompt notice describing such event, the effect thereof and the
actions being taken to avoid or remedy such force majeure; provided, however,
that in no event shall a Party be required to settle any labor dispute or
disturbance.

          18.4    Further Actions.  Each Party agrees to execute, acknowledge
and deliver such further instruments, and to do all such other acts, as may be
necessary or appropriate in order to carry out the purposes and intent of this
Agreement.

28.

          18.5    Notices.  All notices hereunder shall be in writing
and shall be deemed to have been served properly if:  (a) delivered personally; (b) delivered by facsimile transmission
(receipt verified); (c) telexed; (d) mailed by registered or certified air mail
(return receipt requested) postage prepaid; or (e) sent by express courier
service and properly addressed, to the Parties at the following addresses (or
at such other address for a Party as shall be specified by like notice;
provided that notices of a change of address shall be effective only upon
receipt thereof).  Facsimile and telex transmissions shall be deemed received on the first business day following a
confirmed transmission, and a mailed notice or document shall be deemed received on the fifth (5th) business day following the date of posting.

	
   
	
  If to
  VaxGen:
	
  VaxGen, Inc.
  
	
   

	
   
	
   
	
  1000 Marina
  Boulevard
	
   

	
   
	
   
	
  Brisbane,
  California  94005-1841 
	
   

	
   
	
   
	
  Attention:       Chief
  Executive Officer 
	
   

	
   
	
   
	
  Telephone:      (650)
  624-1002
	
   

	
   
	
   
	
  Facsimile:       (650)
  624-1003
	
   

	
   
	
  With copies
  to:
	
  Cooley
  Godward LLP
	
   

	
   
	
   
	
  5 Palo Alto
  Square
	
   

	
   
	
   
	
  3000 El
  Camino Real
	
   

	
   
	
   
	
  Palo Alto,
  California  94306
	
   

	
   
	
   
	
  Attention:       Barbara
  A. Kosacz
	
   

	
   
	
   
	
  Telephone:      (650)
  843-5818
	
   

	
   
	
   
	
  Facsimile:       (650)
  849-7400
	
   

	
   
	
   
	
   
	
   

	
   
	
  If to
  Kaketsuken:
	
  Kaketsuken 
	
   

	
   
	
   
	
  1-6-1 Okubo,
  Kumamoto-shi
	
   

	
   
	
   
	
  Kumamoto
  860-8568, Japan
	
   

	
   
	
   
	
  Attention:
	
   

	
   
	
   
	
  Telephone:
	
   

	
   
	
   
	
  Facsimile:
	
   

          With copies
to:

          18.6    Waiver.  Except as specifically provided for herein,
the waiver from time to time by either of the Parties of any of their rights or
their failure to exercise any remedy shall not operate or be construed as a
continuing waiver of same or any other of such Party’s rights or remedies
provided in this Agreement.

          18.7    Severability.  If any term, covenant or condition of this
Agreement or the application thereof to any Party or circumstances shall, to
any extent, be held to be invalid or unenforceable, then:  (i) the remainder of this Agreement, or the
application of such term, covenant or condition to Parties or circumstances
other than those as to which it is held invalid or unenforceable, shall not be
affected thereby and each term, covenant or condition of this Agreement shall
be valid and be enforced to the fullest extent permitted by law; and (ii) the
Parties hereto covenant and agree to renegotiate any such term, covenant or
application thereof in good faith in order to provide a reasonably acceptable
alternative to the term, covenant or condition of this Agreement or the
application thereof that is invalid or unenforceable, it being the intent of
the Parties that the basic purposes of this Agreement are to be effectuated.

29.

          18.8    Headings.  The Articles and Sections headings contained
herein are for the purposes of convenience only and are not intended to define
or limit the contents of the Articles or Sections paragraphs to which they
apply.

          18.9    Counterparts.  This Agreement may be executed in one or
more counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.

          18.10   Entire Agreement; Amendments.  This Agreement, including all Exhibits
attached thereto, sets forth all the covenants, promises, agreements,
warranties, representations, conditions and understandings between the Parties
hereto with respect to the subject matter thereof, and supersede and terminate
all prior agreements and understandings between the Parties with respect to
such subject matter.  There are no
covenants, promises, agreements, warranties, representations, conditions or
understandings, either oral or written, between the Parties with respect to the
subject matter thereof other than as set forth therein.  No subsequent alteration, amendment, change
or addition to the Agreement shall be binding upon the Parties hereto unless
reduced to writing and signed by the respective authorized officers of the
Parties.  The Agreement, including
without limitation the Exhibits and attachments thereto, are intended to define
the full extent of the legally enforceable undertakings of the Parties thereto
with respect to the subject matter thereof, and no promise or representation,
written or oral, which is not set forth explicitly is intended by either Party
to be legally binding.  Both Parties
acknowledge that in deciding to enter into the Agreement and to consummate the
transaction contemplated thereby neither Party has relied upon any statement or
representations, written or oral, other than those explicitly set forth
therein.

          18.11   Independent Contractors.  The status of the Parties under this
Agreement shall be that of independent contractors.  Neither Party shall have the right to enter into any agreements
on behalf of the other Party, nor shall it represent to any person that it has
any such right or authority.  Nothing in
this Agreement shall be construed as establishing a partnership or joint
venture relationship between the Parties.

          18.12   Currency.  The references in this Agreement to amounts
expressed in dollars ($) shall mean United States dollars.

          18.13   English Language.  This Agreement has
been drafted in the English language, and the English language shall control
its interpretation. 

30.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED.

31.

          IN WITNESS
WHEREOF, Kaketsuken and VaxGen have caused this
Agreement to be executed as of the date first written above by their respective
officers thereunto duly authorized.

	
  VAXGEN
	
   
	
  KAKETSUKEN
	
   

	
   
	
   
	
   
	
   

	
  By:  /s/ Lance Gordon
	
   
	
  By:  /s/ Kyoji Uchino
	
   

	
   
	
  

  	
   
	
   
	
  

  	
   

	
   
	
   
	
   
	
   

	
  Name:  Lance Gordon
	
   
	
  Name:  Kyoji Uchino
	
   

	
   
	
   
	
   
	
   

	
  Title:  Chief Executive Officer
	
   
	
  Title:  Director General, President
	
   

						

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED.

32.

	
  ARTICLE 1  

  	
   
	
  DEFINITIONS
	
  2

	
   
	
  1.1
	
  “Affiliate”
	
  2

	
   
	
  1.2
	
  “Asia”
	
  2

	
   
	
  1.3
	
  “BLA”
	
  2

	
   
	
  1.4
	
  “Bulk
  Product”
	
  2

	
   
	
  1.5
	
  “Calendar
  Year”
	
  2

	
   
	
  1.6
	
  “CDC”
	
  2

	
   
	
  1.7
	
  “Chiba”
	
  2

	
   
	
  1.8
	
  “Confidential
  Information”
	
  2

	
   
	
  1.9
	
  “Control”
  or “Controlled”
	
  2

	
   
	
  1.10
	
  “Cost
  of Sales”
	
  3

	
   
	
  1.11
	
  “Development
  Activities”
	
  3

	
   
	
  1.12
	
  “Direct
  Costs”
	
  3

	
   
	
  1.13
	
  “Europe”
	
  3

	
   
	
  1.14
	
  “FDA”
	
  3

	
   
	
  1.15
	
  “FD&C
  Act”
	
  3

	
   
	
  1.16
	
  “Field”
	
  3

	
   
	
  1.17
	
  “Finished
  Product”
	
  4

	
   
	
  1.18
	
  “First
  Commercial Sale”
	
  4

	
   
	
  1.19
	
  “Forecast”
	
  4

	
   
	
  1.20
	
  “Good
  Manufacturing Practice” or “cGMP”
	
  4

	
   
	
  1.21
	
  “Gross
  Sales Revenue”
	
  4

	
   
	
  1.22
	
  “IND”
	
  4

	
   
	
  1.23
	
  “Information”
	
  4

	
   
	
  1.24
	
  “Invention”
	
  4

	
   
	
  1.25
	
  “Kaketsuken
  Know-How”
	
  4

	
   
	
  1.26
	
  “Kaketsuken
  Materials”
	
  4

	
   
	
  1.27
	
  “Kaketsuken
  Patents”
	
  4

	
   
	
  1.28
	
  “Marketing
  Costs”
	
  5

	
   
	
  1.29
	
  “Net
  Sales”
	
  5

	
   
	
  1.30
	
  “Operating
  Profit”
	
  5

	
   
	
  1.31
	
  “Other
  Allowable Expenses”
	
  6

	
   
	
  1.32
	
  “Patent”
	
  6

	
   
	
  1.33
	
  “Person”
	
  6

	
   
	
  1.34
	
  “Product
  Labeling”
	
  6

	
   
	
  1.35
	
  “Quality
  Protocol”
	
  6

	
   
	
  1.36
	
  “R&D
  Expenses”
	
  6

	
   
	
  1.37
	
  “Regulatory
  Agency”
	
  7

	
   
	
  1.38
	
  “Regulatory
  Approvals”
	
  7

	
   
	
  1.39
	
  “Regulatory
  and Manufacturing Development Expenses
	
  7

	
   
	
  1.40
	
  “Secondary
  Manufacture” or “Secondary Manufacturing”
	
  7

	
   
	
  1.41
	
  “Specifications”
	
  7

	
   
	
  1.42
	
  “Steering
  Committee”
	
  7

	
   
	
  1.43
	
  “Term”
	
  7

	
   
	
  1.44
	
  “Territory”
	
  7

	
   
	
  1.45
	
  “Third
  Party”
	
  7

	
   
	
  1.46
	
  “Transfer
  Price”
	
  7

	
   
	
  1.47
	
  “TSE”
	
  7

	
   
	
  1.48
	
  “United
  States”
	
  7

	
   
	
  1.49
	
  “USDA”
	
  8

	
   
	
  1.50
	
  “Vaccine”
	
  8

	
   
	
  1.51
	
  “VaxGen
  Know-How”
	
  8

	
   
	
  1.52
	
  “VaxGen
  Patents”
	
  8

	
  ARTICLE 2
	
   
	
  OVERVIEW
	
  8

	
   
	
  2.1
	
  Purpose
	
  8

	
   
	
  2.2
	
  Commercial
  Principles
	
  8

	
   
	
  2.3
	
  Steering
  Committee
	
  8

	
  ARTICLE 3
	
   
	
  LICENSES
	
  9

	
   
	
  3.1
	
  License
  Grant to VaxGen
	
  9

	
   
	
  3.2
	
  Rights
  of First Refusal: Europe
	
  9

	
   
	
  3.3
	
  Negotiation
  Rights:  Other Territories
	
  10

	
   
	
  3.4
	
  Grant-back
  and Use of [ * ]
	
  10

	
  ARTICLE 4  
	
   
	
  NON-CLINICAL
  AND CLINICAL DEVELOPMENT
	
  11

	
   
	
  4.1
	
  Current
  Status
	
  11

	
   
	
  4.2
	
  Development
  Roles in the Territory
	
  11

	
   
	
  4.3
	
  Consent
  for Specific Development Program
	
  11

	
   
	
  4.4
	
  Regulatory
  Applications
	
  12

	
   
	
  4.5
	
  Regulatory
  Meetings and Correspondence
	
  12

	
   
	
  4.6
	
  Expenses
	
  12

	
  ARTICLE 5
	
   
	
  MANUFACTURE
  AND SUPPLY OF MATERIALS FOR DEVELOPMENT PROGRAM
	
  12

	
   
	
  5.1
	
  Supply
  of Bulk Product and Finished Product For Development Program
	
  12

	
  ARTICLE 6
	
   
	
  COMMERCIAL
  MANUFACTURE AND SUPPLY
	
  13

	
   
	
  6.1
	
  General
  Rights and Responsibilities of the Parties
	
  13

	
   
	
  6.2
	
  General
  Principles
	
  13

	
   
	
  6.3
	
  Kaketsuken
  Advisory Role
	
  13

	
   
	
  6.4
	
  Kaketsuken’s
  Production Capacity and Scale-Up
	
  13

	
   
	
  6.5
	
  Forecasting
	
  14

	
   
	
  6.6
	
  Failure
  to Supply
	
  14

	
   
	
  6.7
	
  Facilities
	
  15

	
   
	
  6.8
	
  Specifications
	
  15

	
   
	
  6.9
	
  Delivery
  and Shipment
	
  15

	
   
	
  6.10
	
  Acceptance
  and Rejection
	
  16

	
  ARTICLE 7
	
   
	
  REGULATORY
  ISSUES
	
  17

	
   
	
  7.1
	
  Compliance
	
  17

	
   
	
  7.2
	
  Audits
  By VaxGen
	
  17

	
   
	
  7.3
	
  Regulatory
  Audits
	
  18

	
   
	
  7.4
	
  Quality
  Protocol
	
  18

	
  ARTICLE 8
	
   
	
  TRANSFER
  PRICE; PROFIT SHARING; OTHER PAYMENTS
	
  18

	
   
	
  8.1
	
  Transfer
  Price
	
  18

	
   
	
  8.2
	
  Profit
  Sharing
	
  19

	
   
	
  8.3
	
  Royalty
  and Tech Transfer Payments
	
  21

	
  ARTICLE 9
	
   
	
  PROMOTION
  AND MARKETING; TRADEMARKS
	
  21

	
   
	
  9.1
	
  VaxGen’s
  Sales
	
  21

	
   
	
  9.2
	
  Vaccine
  Trademark
	
  21

	
   
	
  9.3
	
  Promotional
  Materials
	
  22

	
   
	
  9.4
	
  Trade
  Dress, Logos, and the Like
	
  22

	
  ARTICLE 10
	
   
	
  CONFIDENTIAL
  INFORMATION
	
  22

	
   
	
  10.1
	
  Confidential
  Information
	
  22

	
   
	
  10.2
	
  Authorized
  Disclosure
	
  23

	
   
	
  10.3
	
  Publicity
	
  23

	
  ARTICLE 11
	
   
	
  OWNERSHIP OF INTELLECTUAL PROPERTY AND PATENT RIGHTS
	
  24

	
   
	
  11.1
	
  Ownership
	
  24

	
   
	
  11.2
	
  Patent Prosecution
	
  24

	
   
	
  11.3
	
  Enforcement Rights
	
  24

	
   
	
  11.4
	
  Defense and Settlement of Third Party Claims
	
  25

	
  ARTICLE 12
	
   
	
  REPRESENTATIONS AND WARRANTIES
	
  25

	
   
	
  12.1
	
  Mutual Representations and Warranties
	
  25

	
   
	
  12.2
	
  Kaketsuken Representations and Warranties
	
  26

	
   
	
  12.3
	
  VaxGen’s Responsibility for Registration
	
  27

	
   
	
  12.4
	
  Kaketsuken’s Responsibility for Registration
	
  27

	
  ARTICLE 13
	
   
	
  COMPETITIVE TRANSACTIONS
	
  27

	
  ARTICLE 14
	
   
	
  INFORMATION AND REPORTS
	
  28

	
   
	
  14.1
	
  Records
	
  28

	
   
	
  14.2
	
  Complaints
	
  28

	
   
	
  14.3
	
  Adverse Drug Experiences
	
  28

	
   
	
  14.4
	
  Records of Revenues and Expenses
	
  28

	
  ARTICLE 15
	
   
	
  INDEMNIFICATION
	
  29

	
   
	
  15.1
	
  Indemnification by VaxGen
	
  29

	
   
	
  15.2
	
  Indemnification by Kaketsuken
	
  29

	
   
	
  15.3
	
  Indemnification Procedures
	
  29

	
   
	
  15.4
	
  Payment of Damages
	
  30

	
   
	
  15.5
	
  Limitation of Liability
	
  30

	
  ARTICLE 16
	
   
	
  TERM AND TERMINATION
	
  30

	
   
	
  16.1
	
  Term
	
  30

	
   
	
  16.2
	
  Termination for Material Breach
	
  30

	
   
	
  16.3
	
  Termination by VaxGen
	
  30

	
   
	
  16.4
	
  Termination by Kaketsuken
	
  30

	
   
	
  16.5
	
  Bankruptcy
	
  31

	
   
	
  16.6
	
  Effect of Termination and Expiration
	
  31

	
   
	
  16.7
	
  Vaccine Inventory.
	
  32

	
   
	
  16.8
	
  Surviving Rights
	
  32

	
  ARTICLE 17
	
   
	
  DISPUTE RESOLUTION; GOVERNING LAW
	
  32

	
   
	
  17.1
	
  Disputes
	
  32

	
   
	
  17.2
	
  Governing Law
	
  32

	
  ARTICLE 18
	
   
	
  MISCELLANEOUS
	
  33

	
   
	
  18.1
	
  Assignment
	
  33

	
   
	
  18.2
	
  Consents Not Unreasonably Withheld or Delayed
	
  33

	
   
	
  18.3
	
  Force Majeure
	
  33

	
   
	
  18.4
	
  Further Actions
	
  33

	
   
	
  18.5
	
  Notices
	
  33

	
   
	
  18.6
	
  Waiver
	
  34

	
   
	
  18.7
	
  Severability
	
  34

	
   
	
  18.8
	
  Headings
	
  35

	
   
	
  18.9
	
  Counterparts
	
  35

	
   
	
  18.10
	
  Entire Agreement; Amendments
	
  35

	
   
	
  18.11
	
  Independent Contractors
	
  35

	
   
	
  18.12
	
  Currency
	
  35

	
   
	
  18.13
	
  English Language
	
  35

[ * ] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2
OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

EXHIBIT A

VACCINE
SPECIFICATIONS

Bulk Product Specifications

              [
* ]

Finished Product Specifications

              [
* ]

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED.

EXHIBIT B

VACCINE
ADVERSE EVENT REPORTING

	
  
	
  VACCINE ADVERSE EVENT REPORTING SYSTEM
24 Hour Toll Free Information 1-800-822-7967

  P.O. Box 1100, Rockville, MD 20849-1100

  PATIENT IDENTITY KEPT CONFIDENTIAL
	
    For CDC/FDA Use Only

    VAERS Number _________________

    Date Received _____________________

	
     Patient Name:
	
    Vaccine administered by
  (Name):
	
    Form completed by (Name):

	
   
	
   
	
   
	
   
	
   
	
   
	
   
	
   
	
   

	
      Last 
	
  First
	
  M.I.  
	
     Responsible 
	
     Relation

     to Patient
	
  o Vaccine Provider   
	
  o Patient/Parent

	
   
	
     Physician
	
   
	
   
	
  o Manufacturer
	
  o Other

	
      Address
	
     Facility
  Name/Address
	
     address (if different from patient or provider)

	
   
	
   
	
   
	
   
	
   
	
   
	
   
	
   
	
   

	
   
	
   
	
   
	
   
	
   
	
   
	
   
	
   
	
   

	
   
	
   
	
   
	
   
	
   
	
   
	
   
	
   
	
   

	
   
	
   
	
   
	
   
	
   
	
   
	
   

	
      City
	
  State
	
  Zip
	
     City
	
  State
	
  Zip
	
     City
	
  State
	
  Zip

	
      Telephone no.
  (____) _____________________
	
     Telephone no.
  (____) _______________________
	
     Telephone no.
  (____) _____________________

	
   
	
   
	
   

	
      1. State
	
    2. County where
  administered
	
   3. 
	
   Date of birth
	
   4.
	
   Patient age
	
    5. Sex
	
    6. Date form completed

	
   
	
   
	
   
	
          /       /         
	
   
	
   
	
         o M  o F
	
   
	
          /       /         
	
   

	
   
	
   
	
   
	
  mm    dd    yy   
	
   
	
   
	
   
	
   
	
  mm    dd    yy   
	
   

	
      7. Describe adverse
  events(s) (symptoms, signs, time course) and treatment, if any
	
   8. 
	
   Check all appropriate:

	
   
	
     o Patient died
	
   
  (date
	
          /       /         
	
  )  

	
   
	
     o Life threatneing illness
	
  mm    dd    yy   
	
   

	
   
	
     o Required emergency room/doctor visit

	
   
	
     o Required hospitalization (_ _ _ _ _
  _ _days)

	
   
	
     o Resulted in prolongation of
  hospitalization

	
   
	
     o Resulted in permanent disability

	
   
	
     o None of the above 

	
      9. Patient
  recovered          o  YES  o  NO  o  UNKNOWN
	
   10. 
	
   Date of vaccination
	
   11. 
	
   Adverse event onset

	
    12. Relevant
  diagnostic tests/laboratory data
	
   
	
          /       /         
	
   
	
   
	
          /       /         
	
   

	
   
	
   
	
  mm    dd    yy   
	
   
	
   
	
  mm    dd    yy   
	
   

	
   
	
  AM
  Time _ _ _ _ _
  _ _  PM
	
  AM
  Time _ _ _ _ _
  _ _  PM

	
   
	
  13.
	
   Enter all vaccines given on
  date listed in no. 10  

	Vaccine
  (type)
	Manufacturer
	Lot
  number
	Route/Site
	No.
  Previous

  Doses

	    a. ______________________
	  ________________________
	  ________________________
	  ________________________
	  ________________________

	    b. ______________________
	  ________________________
	  ________________________
	  ________________________
	  ________________________

	    c. ______________________
	  ________________________
	  ________________________
	  ________________________
	  ________________________

	    d. ______________________
	  ________________________
	  ________________________
	  ________________________
	  ________________________

	  
	  
	  
	  
	  

	
    14. Any other
  vaccinations within 4 weeks prior to the date listed in no. 10

	Vaccine
  (type)
	Manufacturer
	Lot
  number
	Route/Site
	No.
  Previous

  Doses
	
  Date

  given

	
      a. __________________
	
    ___________________
	
    ___________________
	
    ___________________
	
    ___________________
	
    ___________________

	
      b. __________________
	
    ___________________
	
    ___________________
	
    ___________________
	
    ___________________
	
    ___________________

	
   
	
   
	
   
	
   
	
   
	
   

	
    15. Vaccinated at:
	
    16. Vaccine purchased
  with:
	
    17. Other medications

	
      o Private doctor’s office/hospital
	
    o Military clinic/hospital
	
     o Private funds
	
    o Military funds
	
   

	
      o Public health clinic/hospital
	
    o Other/unknown
	
     o Public funds
	
    o Other/unknown
	
   

	
    18. Illness at time of
  vaccination (specify)
	
    19. Pre-existing
  physician-diagnosed allergies, birth defects, medical conditions(specify)

	
    20.
	
  Have you reported 

  this adverse event

  previously?
	
  o No 
	
  o To health department 
	
  Only for children 5 and under 

	
   
	
  o To doctor
	
  o To manufacturer
	
    22. Birth weight
	
    23. No. of brother and sisters

	
   
	
    
	
    
	
   _ _ _ _ _ _ _ lb.  _ _ _ _ _ _ 
  oz.   
	
   

	
    21.
	
  Adverse event following  prior vaccination (check all applicable, specify) 
	
   Only for reports submitted by manufacturer/Immunization project

	
   
	
   
	
  Adverse

  Event
	
  Onset

  Age
	
  Type

  Vaccine
	
  Dose no.

  in series
	
    24.
  Mfr./imm. proj. report no.
	
    25.
  Date received by mfr./imm.proj.

	
  o 
	
  In patient
	
  _________
	
  _________
	
  _________
	
  _________
	
   
	
   

	
  o 
	
  In brother
	
  _________
	
  _________
	
  _________
	
  _________
	
    26. 15 day
  report?
	
    27. Report type

	
   
	
  or sister
	
  _________
	
  _________
	
  _________
	
  _________
	
        o Yes     o  No
	
        o 
  Initial      o  Follow-Up

	
  Health
  care providers and manufacturers are required by law (42 USC 300aa-25) to
  report reactions to vaccines listed in the Table of Reportable Events
  Following Immunization Reports for reactions to other vaccines are voluntary except when required as
  a condition of immunization grant awards.

	
  Form VAERS-1(FDA)

																																																												

ii.

EXHIBIT
C

QUALITY PROTOCOL

(There was no Exhibit C attached to the final
signature document.)

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED.

iii.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00064-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00064-of-00352.parquet"}]]